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Serotonin and Schizophrenia
Abstract
Although the serotonin hypothesis of schizophrenia is one of the oldest neurochemical hypotheses on
the pathogenesis of this disease, it is still highly topical. The concept of how the serotonin system is
involved in the origin and progress of schizophrenia has considerably changed over the past decades.
Therefore, the present work will give an overview about the development and the current directions of
the serotonin hypothesis of schizophrenia. In this regard, we will discuss the phenomenology of
hallucinogenic drug action, model psychosis and translational research, post-mortem studies on
receptors and transporters, imaging studies, antipsychotic drug action, neuroendocrine challenge studies,
platelet and cerebrospinal fluid data, genetic association studies, developmental aspects, and the
cross-talk between the glutamate and the serotonin system. In sum, there are several lines of evidence
suggesting that the serotonin system plays a major role in the pathogenesis of at least a subpopulation of
schizophrenia patients. Further studies are needed to better characterize patients whose psychotic
symptoms are suspected to have a serotonergic origin.
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Abstract 
Although the serotonin hypothesis of schizophrenia is one of the oldest neurochemical hypotheses on 
the pathogenesis of this disease, it is still highly topical. The concept of how the serotonin system is 
involved in the origin and progress of schizophrenia has considerably changed over the past decades. 
Therefore, the present work will give an overview about the development and the current directions of 
the serotonin hypothesis of schizophrenia. In this regard, we will discuss the phenomenology of 
hallucinogenic drug action, model psychosis and translational research, post-mortem studies on 
receptors and transporters, imaging studies, antipsychotic drug action, neuroendocrine challenge 
studies, platelet and cerebrospinal fluid data, genetic association studies, developmental aspects, and 
the cross-talk between the glutamate and the serotonin system. In sum, there are several lines of 
evidence suggesting that the serotonin system plays a major role in the pathogenesis of at least a 
subpopulation of schizophrenia patients. Further studies are needed to better characterize patients 
whose psychotic symptoms are suspected to have a serotonergic origin. 
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Introduction 
The symptoms of schizophrenia can be divided into three major domains: (1) positive symptoms such 
as hallucinations, perceptual disturbances, delusional phenomena, and formal thought disorder; (2) 
cognitive dysfunction, which includes motivational and executive function deficits; and (3) negative 
symptoms, including flat affect, poverty of speech, avolition, and inappropriate emotional responses 
(Tamminga and Holcomb, 2005). Presentation of symptoms from these three domains is heterogenous, 
making the illness difficult to diagnose and treat. The highest risk period for developing schizophrenia 
is during young adulthood. Both sexes are equally affected by the disorder, although the age of onset 
of symptoms is typically younger for men than women (Goldstein et al., 1989; Faraone et al., 1994; 
Bromet and Fennig, 1999). Although incidence figures vary depending on the diagnostic criteria, 
schizophrenia affects approximately 1%. Individuals with schizophrenic parents or siblings have an 
increased risk for developing the illness (8-12%). For monozygotic twins, the concordance rate is 
approximately 50% (Holzman and Matthysse, 1990; Gottesman, 1991). The elevated familial 
incidence of schizophrenia strongly indicates that there is a genetic contribution to the disorder, 
although the fact that concordance rates for monozygotic twins are lower than 100% suggests that 
environmental factors are also involved. It is therefore likely that a combination of genetic 
susceptibility and environmental factors are required for the illness to develop (Gottesman, 1991). 
Linkage studies of schizophrenia have identified several chromosomal regions and candidate genes 
that are associated with the disorder (reviewed by Harrison and Owen, 2003; Harrison and 
Weinberger, 2005). 
Although there is evidence for enlarged ventricles and decreased cerebral (cortical and hippocampal) 
volume associated with schizophrenia, there is not a distinct “diagnostic” neuropathology associated 
with the disease (reviewed by Harrison, 1999b, 2004; Harrison and Owen, 2003). Misplaced and 
clustered neurons, particularly in the entorhinal cortex, indicate problems of neuronal migration and 
suggest an early developmental anomaly (Jakob and Beckmann, 1986; Arnold et al., 1991; Falkai et 
al., 2000). Pyramidal neurons in the hippocampus and neocortex have been shown to have smaller cell 
bodies and fewer dendritic spines and dendritic arborizations (reviewed by Harrison and Weinberger, 
2005). Additionally, decreased presynaptic proteins such as synaptophysin, SNAP-25, and complexin 
II have been observed in schizophrenia brains (Harrison and Eastwood, 2001; Honer and Young, 
2004) as well as decreased density of interneurons (e.g., parvalbumin-immunoreactive cells; Lewis, 
2000; Reynolds et al., 2002a). There are also reports of decreases in cell numbers in the thalamus and 
a decreased number of oligodendrocytes. Neuroimaging data and post-mortem studies have shown that 
N-acetylaspartate (NAA), a marker of neuronal integrity, is decreased in first episode and never-
medicated patients (Bertolino and Weinberger, 1999; Nudmamud et al., 2003). Based on these 
neuropathological changes, investigators have conceptualized schizophrenia as a disease of functional 
“dysconnectivity” (Weinberger et al., 1992; Friston and Frith, 1995; McGlashan and Hoffman, 2000), 
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or a “disorder of the synapse” (Mirnics et al., 2001; Frankle et al., 2003) affecting the machinery of the 
synapse (Harrison and Eastwood, 2001; Honer and Young, 2004). 
Not only structural alterations but also neurochemical changes have been proposed to play a role in the 
etiopathogenesis of schizophrenia. In the following sections we give an overview on the serotonin 
hypothesis of schizophrenia. Although it is one of the oldest neurochemical hypotheses on the 
pathogenesis of this disease, it is still highly topical as it will be shown in the following sections. 
 
 
History of the serotonin hypothesis of schizophrenia 
The first step in the direction of the idea that the serotonin system may contribute to schizophrenia was 
probably done by the German psychiatrist Kurt Beringer (1923). He was the first to propose the use of 
the hallucinogen mescaline as an experimental model of psychosis, despite the fact that he had no 
knowledge of serotonin receptors or the principles of neurotransmission. Previously, on the eve of the 
First World War, Knauer and Maloney (1913) already recommended the mescaline self-experience for 
psychiatrists to gain better insights into the psychotic states of their patients. Subsequently, we have 
come to understand that mescaline is a selective serotonin-2A (5-HT2A) receptor agonist that played an 
important role in the development of the transmethylation hypothesis of schizophrenia (see below). In 
1943, Albert Hofmann identified the impressive psychotomimetic effects of d-lysergic acid 
diethylamid (LSD) during an unintentional self-intoxication in his laboratory at Sandoz 
Pharmaceutical Company (Stoll, 1947). During subsequent repeated self-experiments, Hofmann noted 
that the necessary dose of LSD to cause psychological effects was very small, strongly suggesting that 
there must be a receptor or some other specific site of action for the LSD molecule. Mescaline, in 
contrast, had to be given in hundreds of milligrams to produce psychotomimetic effects that were 
comparable to the effects of several micrograms of LSD (Stoll, 1947). Hofmann gave LSD to Walter 
Stoll, a psychiatrist at the University Hospital of Psychiatry Zurich “Burghölzli” and son of 
Hofmann’s supervisor Arthur Stoll at Sandoz. The younger Stoll explored the psychopathological 
effects of LSD in 16 healthy volunteers and found that the LSD effects were striking similar to the 
symptoms of schizophrenia (Stoll, 1947).1 Subsequently, both Stoll and his colleague Condrau 
administered LSD to patients with schizophrenia, hoping that the LSD “shock” may have some 
therapeutic benefits. They noted that LSD is much less potent in schizophrenia patients than in normal 
controls and therefore concluded that a toxic substance similar to LSD may cause schizophrenic 
psychoses (Stoll, 1947; Condrau, 1949; Stoll, 1949). With this perception, they paved the way for the 
transmethylation hypothesis. Moreover, both authors noted that LSD may prove to be a valuable tool 
to induce psychotic states experimentally in the laboratory. 
While searching for a vasoconstrictive substance in platelets, Rapport and colleagues (1948) 
discovered serotonin and soon thereafter the structure of serotonin was deduced (Rapport, 1949). Betty 
                                                 
1 Interestingly, Stoll (1947) already suggested radioactive labeling of LSD to investigate in animals in which 
brain regions LSD acts. 
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Twarog and Irvine Page (1953) subsequently demonstrated that serotonin could be found in the 
mammalian brain. Initially it was thought that serotonin was simply a residue of blood in the brain, but 
the structural similarities between LSD and serotonin led to the suggestion that serotonin may act 
directly in the brain (Healy, 2002). Gaddum (1953) quickly determined that the oxytocic effects of 
serotonin could be antagonized by LSD. As was fashionable at the time among pharmacologists, 
Gaddum took LSD himself. The intense experience encouraged him to propose that serotonin in the 
brain may play a role in preserving sanity (Gaddum and Hameed, 1954; Healy, 2002). At the same 
time, Woolley and Shaw (1953) independently discovered that other centrally acting indoleamines 
(yohimbine, ergot alkaloids, harmine) also antagonize the vasoconstrictive action of serotonin and they 
also concluded that serotonin may play a role in nervous disorders (Woolley and Shaw, 1954). 
Gaddum and Hameed (1954) and Woolley and Shaw (1954) proposed that the serotonin activity might 
be decreased in the brain of schizophrenia patients. Subsequent evidence indicating that LSD is an 
agonist rather than an antagonist put this hypothesis into question (Baumeister and Hawkins, 2004). 
Later Woolley (1962) revoked his initial suggestion and stated that schizophrenia may result from an 
excess of brain serotonin. 
Shortly before the discoveries of Gaddum, Woolley and Shaw, another serotonin-related hypothesis of 
schizophrenia has also appeared. As early as 1932, Henk de Jong noted that mescaline is chemically 
related to epinephrine. He therefore supposed that a disturbance of epinephrine metabolism might lead 
to the synthesis of a mescaline-like substance that causes catatonia, one of the primary forms of 
schizophrenia at that time (de Jong, 1932). Twenty years later, Osmond and Smythies (1952) 
reinvented this idea and proposed the influential transmethylation hypothesis of schizophrenia. 
Osmond and Smythies observed that an asthmatic patient developed psychotic symptoms after he had 
taken old and therefore oxidized epinephrine during an asthmatic attack. In a self-experiment, Osmond 
and his director Abram Hoffer then took adrenochrome – a breakdown product of epinephrine of pink 
color – and reported that it produced hallucinogenic responses (Healy, 2002). These observations lead 
to their assumption that schizophrenia results from an endogenous neurotoxin that is formed by 
aberrant metabolic processes during the biosynthesis of catecholamines. The last step of the 
biosynthesis of epinephrine is methylation of the amino group of norepinephrine. If the phenolic 
hydroxyl groups were irregularly methylated instead, then a mescaline-like compound would be 
produced. Later Hoffer, Osmond and Smythies (1991) expanded the transmethylation hypothesis by 
proposing the possibility of an aberrant endogenous biosynthesis of methylated indolamine 
hallucinogens such as LSD. In the following years, many researchers tried to find the “pink spot” of 
adrenochrome and other suspected endogenous neurotoxins in the brain, blood, or urine of 
schizophrenia patients. But in the end it was never convincingly found. Moreover, Hoffer and Osmond 
brought their theory directly to the clinic and treated schizophrenia patients with large doses of 
nicotinic acid because it acts to trap methyl donors; thus, the aberrant transmethylation of 
catecholamines or indolamines should be decreased. The authors reported that nicotinic acid alone, as 
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well as in combination with chlorpromazine, had some beneficial effects in the treatment of 
schizophrenia but these results could not be replicated in later studies done by the Canadian 
Association of Mental Health (Healy, 2002). Although the transmethylation hypothesis still has strong 
face validity, it fell out of favor after the 1960s for two reasons: First, the schizophrenogenic 
substances could not be isolated, and secondly, a new influential theory targeting another 
neurotransmitter commandeered the focus of schizophrenia research. For the time being, the serotonin 
hypotheses were superseded by the influential dopamine hypothesis of schizophrenia. 
 
 
The dopamine hypothesis of schizophrenia 
Based on the finding of Brodie et al. (1955; 1956) that reserpine acutely releases brain serotonin while 
postacutely depeleting it, the group of Arvid Carlsson demonstrated that reserpine has the same effect 
on catecholamines (Bertler et al., 1956). These results suggested that serotonin and catecholamines 
may play a role in the sedative and motor depressant effects of reserpine. Carlsson et al. (1957) tested 
this hypothesis by administering the precursors L-dopa and 5-hydroxytryptophan to animals after a 
pretreatment with reserpine. Only L-dopa attenuated the behavioral effects of reserpine, whereas 5-
hydroxytrptophan had no effect. Subsequently, it was shown that L-dopa only increases brain 
dopamine but not norepinephrine (Carlsson, 1959). These results suggested an important role of 
dopamine in brain function. In 1963, Carlsson and Lindquist reported that chlorpromazine and 
haloperidol reduced catecholamine activity through a postsynaptic action (Carlsson and Lindqvist, 
1963). Later van Rossum (1966) explicated that blockade of postsynaptic dopamine receptors is 
responsible for the behavioral effects of these neuroleptic drugs. The dopamine hypothesis of 
schizophrenia – which is actually a hypothesis of neuroleptic drug action – was born. For more than 
three decades, the dopamine hypothesis has dominated biological research on the etiopathogenesis of 
schizophrenia. The assumption that schizophrenia is caused by a significant disturbance of dopamine 
transmission (or metabolism) that results in an increase of dopamine function was initially supported 
by the following data (Bleich et al., 1988): 
 
1). All (admitted) antipsychotic drugs are dopamine-D2 (D2) receptor antagonists and before the 
advent of “atypical” antipsychotics 20 yeas ago it was shown that antipsychotic potency of the 
neuroleptics was directly correlated with D2 receptor binding (Meltzer and Stahl, 1976; Seeman, 
1987). However, the latter is not true for clozapine, which is still the gold standard of 
antipsychotic drug action, because it has only a moderate affinity for D2 receptors but higher 
affinity for 5-HT2A, 5-HT2C, 5-HT6 and 5-HT7 receptors as well as for D4, histamine H1, 
muscarinic M1, α1, and α2 receptors (Arnt and Skarsfeldt, 1998; Abi-Dargham and Krystal, 2000). 
 
2). Sustained or high-dose exposure to indirect dopamine agonists (e.g., L-dopa, cocaine, 
amphetamine) may cause psychotic symptoms in healthy subjects that are similar to paranoid 
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schizophrenia (Segal et al., 1981). Moreover, indirect dopamine agonists provoke exacerbation of 
symptoms in schizophrenia patients. Amphetamine is known to release presynaptic dopamine and 
norepinephrine and it was shown that antipsychotics could improve the acute symptoms of 
amphetamine psychosis (Snyder, 1973; Carlsson, 1988). Nevertheless, psychotic states induced by 
indirect dopamine agonists mimic only the positive symptoms of schizophrenia; thus, maybe only 
the positive symptoms might be due to an increased dopaminergic activity (Angrist and Gershon, 
1970). 
 
3). Postmortem studies and imaging studies with positron emission tomography (PET) initially 
indicate an increase of striatal D2 receptor levels in the brains of schizophrenia patients (Wong et 
al., 1986; Seeman, 1987). However, upregulation of D2 receptor expression could be the result of 
adaptation to antipsychotic drug treatment rather than a pathological abnormality inherent to 
schizophrenia, and, in fact, many postmortem and PET studies could not replicate the finding of 
increased striatal D2 receptor density in drug-naïve schizophrenia patients (Harrison, 1999b; 
Weinberger and Laruelle, 2002). However, there is accumulating evidence for a presynaptic 
dopaminergic abnormality in schizophrenia, implying disturbances in presynaptic storage, 
vesicular transport, release, reuptake, and metabolic mechanisms in mesolimbic dopamine systems 
(Laruelle et al., 1999; Weinberger and Laruelle, 2002). 
 
The current view on the role of dopamine in schizophrenia is that subcortical mesolimbic dopamine 
projections might be hyperactive (causing productive symptoms) and that the mesocortical dopamine 
projections to the prefrontal cortex (PFC) and the anterior cingulate are hypoactive (causing negative 
symptoms and cognitive impairment). These two dysfunctions might be linked as the cortical 
dopamine system generally inhibits the subcortical dopamine system (Weinberger and Laruelle, 2002). 
Addressing the psychopathological heterogeneity of schizophrenia Timothy Crow (1980a; 1980b) 
proposed that schizophrenia can be divided into two syndromes: The type I syndrome is characterized 
by positive symptoms that reflect an increase in striatal dopamine function, and responds well to 
antipsychotics. The type II is more characterized by negative symptoms, structural brain abnormalities 
(cortical atrophy and/or ventricular enlargement), and limited response to (typical) antipsychotics. 
Bleich et al. (1988) suggested that the type II syndrome might respond better to serotonin antagonistic 
compounds, and, thus, he proposed a dopaminergic and serotonergic form of schizophrenia. This view 
is supported by the fact that some atypical substances having a strong 5-HT2A receptor antagonistic 
component may be superior in the treatment of negative symptoms when compared to typical 
neuroleptics without a strong serotonin antagonistic action (Meltzer, 1999). The fact that amisulpride, 
a pure D2/D3 antagonist, has nevertheless a strong impact not only on positive but also on negative 
symptoms maybe due to its unique pharmacokinetic properties (Leucht, 2004). 
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Phenomenology of hallucinogenic drug action 
 
Effects of hallucinogens in human subjects 
Serotonergic hallucinogens produce profound alterations in thought, mood, affect, and sensory 
perception. The effects of these drugs are often characterized by visual illusions and elementary 
hallucinations, altered sense of time and space, and depersonalization. Hallucinogen-induced Altered 
States of Consciousness (ASCs) are highly subjective and are typically assessed using self-reports. 
Various rating scales have been used to assess the effects of hallucinogens (reviewed by Strassman, 
1995). The Addiction Research Center Inventory (Haertzen et al., 1963; Benneyworth et al.) is an 
older instrument that emphasized the unpleasant effects of hallucinogens. The Hallucinogen Rating 
Scale (HRS) was designed specifically to detect the effects of intravenous N,N-dimethyltryptamine 
(Strassman et al.), and has now been validated for other hallucinogens (Gouzoulis-Mayfrank et al., 
1999). Another rating scale, the Altered States of Consciousness Questionnaire (APZ), was developed 
by Dittrich to assess various types of ASCs, independent of their etiology (Dittrich, 1998). The 
original APZ includes three dimensions that have been labeled: Oceanic Boundlessness (OB); Anxious 
Ego Dissolution (AED); and Visionary Restructuralization (VR). The OB dimension measures states 
that resemble mystical experiences, the AED dimension reflects “bad trip”-like experiences, and the 
VR dimension refers to altered visual perceptions. An updated version of the APZ, the 5D-ASC, 
includes two additional dimensions: Reduction of Vigilance (RV) and Auditory Alterations (AA). For 
a detailed description of the APZ and 5D-ASC core dimensions, see Table 1. 
Clinical studies have demonstrated that psilocybin, DMT, and mescaline increase scores in the OB, 
AED, and VR dimensions of the APZ (Hermle et al., 1992; Vollenweider et al., 1997b; Dittrich, 1998; 
Gouzoulis-Mayfrank et al., 1999). Additional studies have shown that psilocybin produces a dose-
dependent increase of scores in the five core dimensions of the 5D-ASC rating scale (Hasler et al., 
2004). However, AED and AA scores are increased significantly only after administration of a high 
dose of psilocybin (0.315 mg/kg, p.o.), and are relatively unaffected by lower doses (0.045–0.215 
mg/kg). 
A large amount of preclinical evidence indicates that the 5-HT2A receptor mediates most of the 
behavioral effects of hallucinogens. Pretreatment with the 5-HT2A antagonist ketanserin blocks the 
effects of psilocybin on the APZ in human volunteers (Vollenweider et al., 1998), confirming the 
involvement of the 5-HT2A receptor. According to a recent PET study with [18F]altanserin, the ability 
of psilocybin to increase 5D-ASC scores is directly correlated with the level of 5-HT2A receptor 
occupation in the anterior cingulate cortex and medial PFC (Hasler, Quednow, Vollenweider, 
unpublished data, see Figure 1). These findings are consistent with those of a [18F]fluorodeoxyglucose 
PET study (Vollenweider et al., 1997b), which found that the effects of psilocybin on the APZ are 
correlated with increases in PFC and anterior cingulate metabolic activity. 
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Table 1. Core dimensions of the 5D-ASC (Dittrich, 1998). 
Dimension Symptoms assessed 
Oceanic Boundlessness (OB) Positive derealization 
Positive depersonalization 
Altered sense of time 
Positive mood 
Mania-like experience 
Anxious Ego Dissolution (AED) Anxious derealization 
Thought disorder 
Delusion 
Fear of loss of control 
Visionary Restructuralization (VR) Elementary hallucinations 
Visual pseudohallucinations 
Synesthesia 
Changed meaning of percepts 
Facilitated recollection 
Facilitated imagination 
Auditory Alterations (AA) Auditory illusions 
Auditory pseudohallucinations 
Reduction of Vigilance (RV) Drowsiness 
Decreased alertness 
Impaired cognitive function 
 
 
Figure 1: Inverse Correlation of 5D-ASC Global Scale scores and [18F]altanserin apparent 
distribution volume [DV’]. Results of a voxel based correlation analysis (Δ 5D-ASC global vs. Δ DV’, 
threshold p<.005, uncorrected) using Statistical Parametric Mapping (SPM2) (Hasler, Quednow, 
Vollenweider, unpublished data). 
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Comparison of hallucinogen effects and endogenous psychoses 
As noted earlier, Beringer was the first investigator to propose that hallucinogens could be used to 
produce a “model psychosis” in healthy humans (Beringer, 1923). Subsequent investigations 
confirmed that administration of mescaline, psilocybin, and LSD induces states that resemble the 
symptoms of the earliest phases of schizophrenia (Rinkel et al., 1952; Rinkel et al., 1955; Keeler, 
1965; Bowers and Freedman, 1966). Indeed, the loss of control over thought processes that occurs 
after ingestion of psilocybin (Vollenweider et al., 1997b) closely parallels acute psychotic 
decompensation (Keeler, 1965; Bowers and Freedman, 1966). Despite these similarities, Hollister 
(1962) and other clinicians have argued that there are notable differences between the effects of 
hallucinogens and the symptomatology of schizophrenia, leading them to question whether 
hallucinogen-induced psychedelic phenomena is a valid model for endogenous psychotic states. For 
example, Hollister noted that auditory but not visual hallucinations are prominent in schizophrenia, 
whereas changes of visual perception are a characteristic effect of hallucinogens. However, 
disturbances in visual perception, including hallucinations and synesthesias, do occur during the acute 
phase of schizophrenia (McCabe et al., 1972; Freedman and Chapman, 1973). Hollister (1962) also 
argued that schizophrenics often display social and emotional withdrawal but this effect is rarely 
observed after administration serotonergic hallucinogens. There is evidence, however, that 
administration of hallucinogens, especially at high doses, can sometimes induce withdrawal and states 
resembling catatonia (Gouzoulis-Mayfrank et al., 1998b). 
In a study conducted by Gouzoulis-Mayfrank and colleagues (1998a), the symptoms of schizophrenia 
were assessed using the APZ rating scale. The goal of that investigation was to determine, using 
objective criteria, whether psychotic patients experience hallucinogen-like psychedelic effects. The 
study compared APZ scores from 50 healthy controls and 93 patients with acute schizophrenia, 
schizophreniform disorder, or schizoaffective disorder. The APZ scores of psychotic patients were 
found to be significantly higher than those of controls. The study also examined whether the APZ 
scores correlate with scores on the Brief Psychiatric Rating Scale (BPRS), which measures positive 
symptoms and general psychopathology. Correlation analysis revealed that the OB subscale of the 
APZ correlates with BPRS factor 3 (reflecting most of the typical positive symptoms of 
schizophrenia), whereas the AED subscale correlates with BPRS factor 1 (reflecting anxiety and 
depression). These findings confirm that patients with acute schizophrenia experience hallucinogen-
like effects, indicating that the syndrome induced by hallucinogens is a valid model of acute 
schizophrenia. 
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Animal models of hallucinogen effects relevant to schizophrenia 
In laboratory animals, serotonergic hallucinogens have been shown to 1) potentiate neophobia (Tilson 
et al., 1975; Adams and Geyer, 1982, 1985), 2) increase the responsiveness to sensory stimulation 
(Key, 1964; Geyer et al., 1978; Geyer, 1998), and 3) retard habituation in a variety of input modalities 
and response output systems (Key, 1964; Geyer et al., 1978; Geyer, 1998; Dulawa and Geyer, 2000; 
Geyer and Moghaddam, 2002). Given the similarities between the psychedelic state induced by 
hallucinogens and the symptoms of acute schizophrenia, there has been substantial interest in 
developing animals models of schizophrenia based on the acute behavioral effects of hallucinogens 
(Geyer and Vollenweider, 2008). Unfortunately, many of the unconditioned behaviors induced by 
hallucinogens in animals (e.g., head-twitch response, ear scratch) have no human counterpart, and thus 
it is not clear how these behaviors relate to the subjective effects of hallucinogens. However, 
hallucinogens produce effects on habituation and prepulse inhibition (PPI) of startle in animals that are 
analogous to hallucinogen effects in humans. Based partially on these cross-species similarities, the 
effects of hallucinogens on habituation and PPI have been proposed as potential behavioral models of 
schizophrenia (reviewed by Powell and Geyer, 2007). A brief description of these two behavioral 
models is provided below. 
 
Habituation 
Repeated presentation of irrelevant stimuli leads to a marked response decrement, a process known as 
habituation. Habituation is the simplest form of learning, and is necessary for selective attention. 
Deficits of attention and information-processing are core features of schizophrenia (Braff, 1985; Braff 
and Geyer, 1990). Patients with schizophrenia are often unable to filter out extraneous stimuli, leading 
to distractibility, sensory flooding, and impaired cognition (McGhie and Chapman, 1961). Several 
studies have found that schizophrenic patients show deficits of startle reflex habituation, potentially 
contributing to the sensory overload and disorganized cognitive processes that occur in the disorder 
(e.g. Geyer and Braff, 1982, 1987; Bolino et al., 1994; Parwani et al., 2000; Ludewig et al., 2003; 
Quednow et al., 2006). An advantage of using habituation as a behavioral model is that similar testing 
procedures can be used to assess habituation in experimental animals and humans. For example, LSD 
and mescaline have been shown to decrease habituation to startling tactile stimuli in rats (Geyer et al., 
1978; Braff and Geyer, 1980), similar to the finding in patients with schizophrenia. 
 
Prepulse inhibition 
The PPI paradigm has been multiply applied in order to assess the loss of sensorimotor gating 
functions in schizophrenia. PPI refers to the fact that weak prestimuli presented at brief intervals (30-
500 ms) prior to a startle-eliciting stimulus reduce, or gate, the amplitude of the startle response. 
Studies have consistently detected robust PPI deficits in schizophrenia patients (e.g. Braff et al., 1978; 
Braff and Geyer, 1990; Bolino et al., 1994; Parwani et al., 2000; Ludewig et al., 2003; Quednow et al., 
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2006). It was proposed that the mechanism underlying PPI regulates sensory input by filtering out 
irrelevant or distracting stimuli in order to prevent sensory information overflow and to allow for 
selective and efficient processing of relevant information (Swerdlow and Geyer, 1998). The 
consistently reported PPI deficits in schizophrenia patients contributed to the view that schizophrenia 
could be seen as gating- or filter-deficit disorder (Carlsson, 1995). As detailed in the previous chapter 
of Halberstadt and Nichols, hallucinogens such as LSD and DOI also disrupt PPI. Thus, the 
hallucinogen-treated animals tested in the PPI paradigm exhibit an increased or unfiltered 
responsiveness to sensory stimuli. That is, they fail to exhibit the gating or inhibition of the response 
normally produced by the prepulse stimulus. As reviewed elsewhere (Geyer et al., 2001; Swerdlow et 
al., 2001), this cross-species phenomenon of PPI is very robust, unlearned, and ubiquitous. Indeed, 
depending on the testing parameters used, the hallucinogen psilocybin has been shown to produce PPI 
deficits in normal human volunteers (Vollenweider et al., 2007). Hence, the ability of hallucinogens to 
alter PPI has been considered to be a useful model to study the positive symptoms of schizophrenia. 
 
 
Serotonin receptor and transporter changes in vivo and postmortem in schizophrenia 
Early postmortem studies with schizophrenia patients revealed that 5-HT and 5-hydroxyindoleacetic 
acid (5-HIAA) levels were increased in subcortical brain regions such as the putamen, nucleus 
accumbens, and globus pallidus (Crow et al., 1979; Farley et al., 1980), and that 5-HIAA levels are 
decreased in cortical regions including cingulate and frontal areas (Winblad et al., 1979). Many 
subsequent studies investigated altered serotonin receptor and transporter expression in schizophrenia 
patients in vivo and postmortem, especially with radiolabeled compounds. Most of these receptor 
investigations explored the 5-HT1A or 5-HT2A receptor density usually with highly divergent results. 
 
5-HT1A receptors 
Among the most consistent alterations of 5-HT parameters in schizophrenia, as identified in 
postmortem studies, is an increase in the density of 5-HT1A receptors in the PFC (Bantick et al., 2001; 
Weinberger and Laruelle, 2002). Seven of ten studies – using either [3H]8-hydroxy-2,3-
(dipropylamino)-tetralin ([3H]8-OH-DPAT) or the more specific compound [3H]WAY-100653 for 5-
HT1A receptor binding and audioradiography, and/or analysis of receptor mRNA – have reported a 15-
80% increase in 5-HT1A receptor levels in the dorsolateral or orbital PFC, whereas other brain regions 
such as the anterior cingulate cortex and the temporal cortex showed less consistent results, including 
possible increases (for review and citations see Bantick et al., 2001; and Gray et al., 2006). 
Interestingly, the increase in prefrontal 5-HT1A receptor density was not necessarily accompanied by a 
change in 5-HT1A receptor mRNA (Burnet et al., 1996b). Moreover, the only study that stained for 5-
HT1A-like immunoreactivity did not find differences between schizophrenia patients and controls 
(Cruz et al., 2004). Since receptors located at other cellular locations could not be visualized with the 
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antibody used, changes in the overall density of the 5-HT1A receptor could not be excluded by this 
study. 
 
In contrast to the consistent findings in postmortem studies, recent investigations of 5-HT1A receptor 
distribution using [11C]WAY-100653 PET in schizophrenia patients are contradictory. One study 
reported increased binding only in the medial temporal lobe (Tauscher et al., 2002), another study 
described decreased binding in the amygdala (Yasuno et al., 2004), whereas two further studies found 
no alterations in cortical 5-HT1A receptor binding (Bantick et al., 2004; Frankle et al., 2006). 
Moreover, Bantick et al. (2004) found no differences in 5-HT1A receptor binding between clozapine-
treated patients, patients medicated with antipsychotics with low 5-HT1A affinity, and healthy human 
volunteers. The authors concluded that clozapine did not occupy 5-HT1A receptors at clinical doses. 
With respect to the inconsistencies between PET and postmortem studies, Frankle et al. (2006) 
suggested that the alterations found in postmortem studies cannot be reliably detected in PET studies, 
which puts into question whether 5-HT1A receptors play a major role in the pathophysiology of 
schizophrenia. Due to the fact that schizophrenia patients included in postmortem studies are rarely 
antipsychotic-naïve, whereas PET studies have mostly assessed in drug-naïve or unmedicated patients, 
it is likely that the 5-HT1A receptor changes found in the majority of postmortem studies are probably 
the result of chronic medication with antipsychotics or other psychotropics. However, in two of the 
postmortem studies, 5-HT1A receptor increases were seen also in drug-free patients (Hashimoto et al., 
1991; Sumiyoshi et al., 1996).  
In sum, findings with respect to 5-HT1A receptor changes are highly contradictory. Whereas 
postmortem studies consistently suggest an increase of 5-HT1A receptor especially in the PFC, PET 
studies did not find changes of prefrontal receptor binding. Effects of chronic antipsychotic medication 
may contribute to these different results. When schizophrenia patients actually display frontal 
upregulation in 5-HT1A receptors, this might reflect an abnormal glutamatergic network because in the 
neocortex these receptors are mainly located on pyramidal cells (Bantick et al., 2001). 
 
5-HT2A receptors 
The 5-HT2A receptor is the most intensively investigated 5-HT receptor in postmortem schizophrenia 
studies in the last 30 years. Fourteen out of eighteen postmortem studies reported finding decreased 5-
HT2A receptor binding/densities (or decreased 5-HT2A receptor mRNA expression) in cortical areas, 
especially in the frontal cortex, of schizophrenia patients (for references and details see Table 2). Two 
of the studies reported an increase in several brain regions, whereas the two remaining studies did not 
find 5-HT2A receptor changes. Moreover, only five investigations explored 5-HT2A receptors in the 
basal ganglia, but only one report suggested increased 5-HT2A levels, whereas the other four studies 
found no changes. It should be noted that the radioligands that were used in these studies have high-
affinity for 5-HT2A receptors, but they also label other receptor types. For example, ketanserin 
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additionally labels α-adrenoreceptors, histamine H1 receptors, and vesicular monoamine transporters; 
LSD binds to 5-HT1A, 5-HT1E, 5-HT2C, 5-HT6, 5-HT7, and dopamine-D1 receptors; whereas spiperone 
also has high affinity for D2 receptors (Harrison, 1999a). This lack of specificity must be taken into 
account when these studies are interpreted.  
Legitimately, the question has been raised whether these receptor changes are simply the result of 
chronic drug treatment, because most of the patients studied were treated with antipsychotics for many 
years. Indeed, it was shown that long-term treatment with clozapine decreases 5-HT2A receptor 
binding and mRNA expression in the cingulate and frontal cortex of rats. In contrast, haloperidol did 
not alter cortical 5-HT2A receptor density or expression in the frontal cortex of rats (Reynolds et al., 
1983a; Wilmot and Szczepanik, 1989; O'Dell et al., 1990; Burnet et al., 1996a). Other atypical 
antipsychotics that are 5-HT2A antagonists may also reduce cortical 5-HT2A receptors when given 
chronically (Mikuni and Meltzer, 1984; Andree et al., 1986; Padin et al., 2006). However, particularly 
in the early studies only a very small number of patients were treated with clozapine or other atypical 
substances. Additionally, antipsychotic medication may increase rather than decrease 5-HT2A receptor 
expression (Hernandez and Sokolov, 2000), and many studies found decreased 5-HT2A receptor 
densities also in unmedicated subjects, or did not detect dose-effects of previous antipsychotic drug 
treatment (see Table 2). Thus, the decrease of 5-HT2A receptors especially in the dorsolateral PFC 
could not be explained only by chronic drug treatment but a pathological process has to be involved 
(Dean, 2003). 
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Table 2: Postmortem studies investigating 5-HT2A receptor density in schizophrenia (modified and updated according to Harrison, 1999a). 
Study Method1 Brain region2 Cases/controls Medicated cases Main findings 
Decrease in cortical binding      
Bennett et al. (1979) HB with [3H]LSD BA 6, 8-11, 44-47 26/253 18 ↓40-50%, no effect of medication 
Mita et al. (1986) HB with [3H]ketanserin BA 9 11/9 7 ↓36%, no effect of medication 
Arora & Meltzer (1991) HB with [3H]spiperone BA 8/9 11/11 11 ↓33%, no effect of medication 
Laruelle et al. (1993a) HB with [3H]ketanserin BA 10, 17/18 10/124 6 ↓21% in BA 10, no effect of medication 
Burnet et al. (1996b) a) RA with [3H]ketanserin BA 17, 22, 46, MTL, AC 13/15 12 ↓27% in BA 46, ↓38% MTL, similar trend in AC 
 b) mRNA using ISH    ↓49-63% in BA 17, 22, 46, AC, ↔ in MTL 
Dean & Hayes (1996) RA with [3H]ketanserin BA 8, 9 10 20/20 19 ↓25-33% in all frontal regions 
Gurevich & Joyce (1997) RA with [125I]LSD BA 1-3, 4, 6, 8, 9, 31, 32, 40, 44-
46, AC, PC 
10/12 5 ↓~60% in BA 6, 24 in drug-free cases, ↓~70-90% in 
all brain regions in medicated cases 
Kouzmenko et al. (1997) RA with [3H]ketanserin BA 9/46 63/625 60 ↓33% 
Dean et al. (1998) RA with [3H]ketanserin BA 9 55/55 55 ↓33% 
Dean et al. (1999a) RA with [3H]ketanserin BA 9 19/19 17 ↓35% 
Hernandez & Sokolov (2000) mRNA using ISH BA 9 21/14 18 ↓60% in patients being drug free for >26 weeks, 
antipsychotic treatment increased 5-HT2A mRNA 
Pralong et al. (2000) a) RA with [3H]ketanserin BA 22 (planum temporale) 20/20 17 ↓32% 
 b) HB with [3H]ketanserin BA 22 (planum temporale) 10/10 10 ↓34% Bmax,↑119%, changes in affinity (Kd) but not 
density (Bmax) explained by medication effects 
Scarr et al. (2004) RA with [3H]ketanserin MTL (only hippocampus) 20/20 20 ↓~29-47% across different regions of hippocampus 
Matsumoto et al. (2005) RA with [3H]ketanserin BA 9, MTL 6/6 6 ↓39% in BA 9, ↔ in MTL 
Increase in cortical binding      
Whitaker et al. (1981) HB with [3H]LSD BA 4, 10, 11 13/8 8 ↔, ↑55% in unmedicated cases 
Joyce et al. (1993) RA with [125I]LSD BA 4, 9, 21, AC, PC, MTL 8/10 4 ↑~50-100% only in MTL, BA 21, PC 
No changes in cortical binding      
Reynolds et al. (1983b) HB with [3H]ketanserin BA 10 11/10 11 ↔ 
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Dean et al. (1996) HB with [3H]ketanserin BA 9 20/20 19 ↔ 
Increase in basal ganglia      
Joyce et al. (1993) RA with [3H]ketanserin Caudate, putamen, NAC 8/10 4 ↑~30-75% 
No changes in basal ganglia      
Mackay et al. (1978) HB with [3H]spiperone NAC 26/17 ? ↔ 
Owen et al. (1981) HB with [3H]LSD, [3H]5-HT Caudate, putamen 19/20 ?12 ↔ 
Seeman et al. (1993) HB with [3H]ketanserin Striatum 9/4 6 ↔ 
Matsumoto et al. (2005) RA with [3H]ketanserin Caudate, putamen 6/6 6 Not significant but strong trend for decrease (↓34%) 
1. HB = homogenate binding; ISH = in situ hybridization; RA = receptor autoradiography. 
2. BA = Brodmann area; BA 4 = motor cortex; BA 6, 8, 9, 10, 11, 44-47 = prefrontal cortex; BA 17/18 = occipital cortex; BA 21, 22 = temporal cortex, AC = anterior cingulate 
cortex; PC = posterior cingulate cortex; MTL = mediotemporal lobe including hippocampus, amygdale, uncus, parahippocampal gyrus, entorhinal cortex; NAC = Nucleus 
accumbens. 
3. Sum of three separate case control groups. The decrease in [3H]LSD binding was demonstrated in all three comparisons. 
4. Includes six subjects with schizoaffective disorder. Significant differences remained when these subjects were excluded. 
5. Included cases of Burnet et al. (1996b) and Dean & Hayes (1996). 
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PET studies applying 5-HT2A receptor tracers to schizophrenia patients show controversial results. 
Three studies using [18F]septoperone and one study using [11C]N-methylspiperone did not show any 
significant differences in 5-HT2A receptor densities between schizophrenia patients and controls; 
neither with regions-of-interest (ROI) based nor with a voxel-based analyses (Trichard et al., 1998; 
Lewis et al., 1999; Okubo et al., 2000; Verhoeff et al., 2000). However, both tracers suffer from a 
relatively low affinity for 5-HT2A receptors and, thus, they have an insufficient signal-to-noise ratio in 
subcortical areas (Erritzoe et al., 2008). In contrast, one study using [18F]septoperone found decreased 
frontal 5-HT2A receptor densities in antipsychotic-naïve schizophrenia patients (-16.3%; Ngan et al., 
2000), while a recently published study using the more selective 5-HT2A antagonist [18F]altanserin 
could not demonstrate a frontal decrease but an increase of 5-HT2A receptors in the caudate in a similar 
patient sample (Erritzoe et al., 2008). Two further studies investigated 5-HT2A receptor density with 
[18F]altanserin PET in subjects supposed to be in a prodromal state of schizophrenia and reported both 
decreased binding of the radio tracer in the PFC (Hurlemann et al., 2005, 2008). In the later study, 
Hurlemann et al. (2008) additionally detected decreased 5-HT2A receptor binding in the right insular 
cortex, left amygdala, both hippocampi, right caudate, and the left putamen in never-medicated 
subjects in a late prodromal stage. Interestingly, a low 5-HT2A receptor density in the right caudate 
predicted later conversion to full-blown psychosis, a finding that is highly discrepant with the results 
of Errizoe et al. (2008). Taken together, in contrast to the consistency of the postmortem findings, the 
PET results are highly contradictory. Given that the methodological differences between the PET 
studies are not really obvious, further studies are needed to clarify if 5-HT2A receptor changes could 
also be detected with an in vivo imaging approach. The new and highly selective 5-HT2A receptor 
radioligand [11C]MDL 100,907 may be a promising tool to further investigate 5-HT2A receptor 
alterations in schizophrenia (Ito et al., 1998). 
 
Other serotonin receptors 
Other serotonin receptor types were investigated in postmortem studies: Two studies using 
[3H]GR113808 autoradiography have shown that the density of 5-HT4 receptors is unaltered in either 
the dorsolateral PFC or the hippocampus of deceased schizophrenia patients when compared to control 
subjects (Dean et al., 1999b; Scarr et al., 2004). A postmortem study investigating the concentration of 
5-HT3 receptors (which is the only ion channel in the 5-HT receptor family) in the amygdala of 
schizophrenia patients and controls with [3H]LY278584 autoradiography did not find group 
differences (Abi-Dargham et al., 1993). The 5-HT6 receptor density measured with [125I]SB-258585 in 
the frontal cortex was not changed in 20 schizophrenia patients compared to 17 control subjects (East 
et al., 2002). Recently, two studies investigated the densities of 5-HT1D and 5-HT1F receptors in the 
dorsolateral PFC and the hippocampus, respectively, of schizophrenia patients using methiothepin-
sensitive and -insensitive [3H]sumatriptane autoradiography (Scarr et al., 2004; Dean et al., 2006). 
While Scarr et al. reported a decrease of 5-HT1F but unaltered 5-HT1D receptors in the hippocampus, 
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Dean et al. did not find any changes in HT1F and 5-HT1D receptors in the dorsolateral PFC of the 
patients. In the same study, however, Dean et al. (2006) found decreased 5-HT7 receptor levels in 
dorsolateral PFC of schizophrenia patients using [3H]SB-269970. By contrast, haloperidol treatment 
increased the number of 5-HT7 receptors in the cortex of rats (Dean et al., 2006). The authors therefore 
concluded that 5-HT7 receptors are possibly involved in the pathological processes of schizophrenia 
and that appropriate 5-HT7 receptor levels may be critical for normal cortical development. These 
recent findings on alterations of HT1F and 5-HT7 receptors in schizophrenia need confirmation by 
further postmortem and – if possible – by PET studies. 
 
Serotonin transporter (SERT) 
Serotonin transporters (SERT) are located presynaptically on serotonergic axon terminals and are 
believed to serve as an index of serotonergic innervation (Abi-Dargham and Krystal, 2000). Two 
postmortem studies applying [3H]cyano-imipramine and [3H]paroxetine have initially shown that the 
density of SERT is decreased in the frontal cortex (Joyce et al., 1993; Laruelle et al., 1993a). In the 
study of Joyce et al., SERT was also decreased in the anterior and posterior cingulate cortex of 
schizophrenia patients but increased in the striatum. On the contrary, later studies using radiolabeled 
serotonin reuptake inhibitors (SRIs), such as [3H]paroxetine, [3H]citalopram, or [125I]RTI-55, did not 
demonstrate any alterations in the SERT density in several brain regions, including the PFC or the 
cingulate cortex, in schizophrenia patients (Dean et al., 1995; Naylor et al., 1996; Gurevich and Joyce, 
1997; Dean et al., 1999b). In fact, three of these studies did not report altered SERT densities but did 
find a decrease in the affinity of [3H]paroxetine for SERT in hippocampal membranes, whereas the 
affinity of [3H]paroxetine for SERT binding in the frontal cortex was unaltered (Dean et al., 1995, 
1996; Naylor et al., 1996). Gurevich and Joyce (Gurevich and Joyce, 1997) concluded that the initial 
positive findings were probably confounded by a large amount of schizophrenia patients who 
committed suicide in the samples. The same may be true for the finding of decreased SRI affinity in 
hippocampal SERT, as Dean et al. (1996) have shown that the effect was more pronounced in 
schizophrenia patients who committed suicide. 
Examining the expression of SERT mRNA, Hernandez and Sokolov (1997) found a four-fold increase 
in the level of SERT mRNA in the dorsolateral PFC but a two-fold decrease in the temporolateral 
cortex of schizophrenics. However, since these changes were strongly correlated with previous 
antipsychotic drug treatment they cannot be attributed to the illness process.  
A SPECT study using [123I]RTI-55 could not detect any differences in SERT concentration in 
midbrain areas of schizophrenia patients (Laruelle et al., 2000). However, [123I]RTI-55 is not specific 
for SERT but also labels the dopamine transporter (DAT) (Neumeyer et al., 1991). In addition, 
[123I]RTI-55 does not permit measurement of SERT availability in regions other than the midbrain 
(Laruelle et al., 1993b). Recently, Frankle et al. (2005) also failed to detect any differences in SERT 
binding between schizophrenia patients and controls when using the more specific radiotracer 
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[11C]DASB. However, [11C]DASB also does not have a good signal-to-noise ratio when assessing 
regions with low SERT density such as the neocortex (Frankle et al., 2005), complicating a possible 
detection of group differences e.g., in the frontal cortex. Thus, taking all of these findings into account, 
it is unlikely that the SERT plays an important role in the pathophysiology of schizophrenia. 
 
 
Genetic association studies regarding schizophrenia and serotonin 
Given that to date more than 1400 association studies searching for potential genetic risk factors have 
been published with largely inconsistent results, a regularly updated online database (“SzGene”) 
including meta-analyses of all published genetic studies for schizophrenia has recently been 
established (Allen et al., 2008; www.schizophreniaforum.org). Single Nucleotide Polymorphisms 
(SNPs) having genotype data available in at least four independent case-control samples were included 
in random-effects meta-analyses using allelic contrasts. In the ranking of the meta-analyses showing 
the strongest effect sizes, two serotonin-related SNPs are currently placed in the top 20 (status March 
30, 2009): The tryptophan hydroxylase 1 (TPH1) A218C polymorphism on rank 9 (odds ratio (OR) = 
1.25), and the 5-HT2A A-1438G polymorphism on rank 15 (OR =1.16). Table 3 displays all serotonin 
SNPs for which meta-analyses were done. For comparison, the strongest effect so far was shown for 
the A2897G polymorphism of the disrupted-in-schizophrenia gene 1 (DISC1; OR = 1.80, Confidence 
interval (CI) = 1.2-2.68). The second rank belongs to the A277C polymorphism of the vesicular 
monoamine transporter 1 (VMAT1; OR = 1.63, Confidence interval (CI) = 1.03-2.57). VMAT1 is 
involved in the intracellular transport of all monoamines including serotonin. The T200G SNP of the 
glutamate receptor subunit GRIN2B (OR = 0.69, CI = 0.54-0.88), is placed on the third rank. These 
ORs reported for schizophrenia susceptibility genes are comparable with those found in other 
genetically complex neuropsychiatric diseases such as Alzheimer’s disease (Allen et al., 2008). 
TPH1 and TPH2 are rate-limiting enzymes in 5-HT synthesis, but while TPH1 is primarily expressed 
in peripheral regions such as the pineal gland and enterochromaffin cells of the gut, TPH2 is expressed 
predominantly in serotonergic neurons of the raphé nuclei (Zhang et al., 2006). Moreover, the TPH1 
A779C and A218C SNPs are intronic (non-coding), and alternative mechanisms probably providing 
gene expression from intronic sequences such as splicing and exon skipping have been ruled out 
(Shaltiel et al., 2005). For these reasons, the positive associations between the TPH1 A218C 
polymorphism and schizophrenia were strongly criticized (Reuter et al., 2007). However, in a 
postmortem study, Zill et al. (2007) recently demonstrated the expression of TPH1 mRNA in several 
brain regions. Therefore, it seems to be largely unclear to date which role TPH1 plays in cerebral 
function and schizophrenia. Most likely, the intronic TPH1 A218C SNP is in linkage disequilibrium 
with other functional as yet unidentified gene variations. Variations of the TPH2 gene have not been 
positively linked to schizophrenia so far (De Luca et al., 2005; Higashi et al., 2007). 
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The positive association findings regarding the 5-HT2A A-1438G polymorphism once more 
underscores the significance of this receptor for schizophrenia (see Table 3). The A-1438G 
polymorphism is silent and does not result in an alteration of the amino acid sequence of the 5-HT2A 
receptor, but is located within the promoter region of the 5-HT2AR gene (Spurlock et al., 1998), and 
thus it has been proposed that the A-1438G polymorphism alters promoter activity and expression of 
5-HT2A receptors (Parsons et al., 2004). The 5-HT2A A-1438G and T102G receptor polymorphisms are 
usually in perfect linkage disequilibrium. We have recently shown that the sensorimotor gating deficits 
of schizophrenia patients – which are seen as a promising endophenotype of schizophrenia (Gottesman 
and Gould, 2003) – are strongly modulated by the 5-HT2A A-1438G and T102C receptor SNPs that 
were completely linked in our sample (Quednow et al., 2008). In accordance to the genetic association 
studies, carriers of the high-risk G- and C-alleles displayed diminished sensorimotor gating. We have 
just replicated this finding in a sample of 94 normal subjects (Quednow et al., 2009). In conclusion, 
the C-allele of the T102C variation and the G-allele of the A-1438G variation may cause lower 5-HT2A 
receptor densities in some brain areas, which may lead to a less flexible serotonin system and worse 
dopaminergic modulation (Serretti et al., 2007). 
The SZGene meta-analyses regarding 5-HT1B G861C, 5-HT2A His452Tyr, 5-HT6 C267T receptor 
SNPs, and the well-known SERT polymorphisms suggest rather weak or no associations with 
schizophrenia (see Table 3).  
Currently, there are also some new interesting data coming from single association studies that still 
have to be replicated. Huang et al. (2004) reported an increased frequency of the G-allele of the 5-
HT1A C-1019G promoter polymorphism in schizophrenia patients. The occurrence of the G-allele is 
associated with enhanced gene expression (Lemonde et al., 2003), which would fit with the 
postmortem data on increased 5-HT1A receptor levels in the PFC of schizophrenics. However, in a 
large postmortem autoradiographic study, Huang et al. (2004) could not demonstrate differences in 5-
HT1A receptor binding between 5-HT1A C-1019G genotypes in suicidal, depressed, and healthy 
subjects. Moreover, significant associations were reported for the 5-HT2C G68C (Segman et al., 2000), 
a 5-HT4 haplotype (Suzuki et al., 2003), several 5-HT5A (Birkett et al., 2000; Iwata et al., 2001; 
Dubertret et al., 2004), and two 5-HT7 receptor polymorphisms (Ikeda et al., 2006). However, there 
were also some negative reports for 5-HT2C G68C (Segman et al., 1997; Semwal et al., 2002), and the 
5-HT7 receptor polymorphisms (Fallin et al., 2005). Further studies are needed to finally assess the 
sustainability of these initial findings. 
 21
Table 3: Meta-analyses of association studies between polymorphisms of the serotonin system and schizophrenia published on the SchizophreniaGene database 
(www.schizophreniaforum.org/res/sczgene/default.asp, status 31. December 2008). Meta-analyses were done for SNPs with a minor allele frequency 
>1%, and when more than three independent case-control samples were available (Allen et al., 2008). 
Gene Substrate SNP1 
Chromosome 
(location) 
Synonymy 
Number of 
studies 
Number of 
patients 
Number of 
controls 
Minor allele 
(% frequency 
in controls) 
Risk 
allele 
Odds ratio4 
(all studies) 
95% 
confidence 
interval  
5-HT1B receptor rs6296 (G861C) 6 (6q13) synonymous 4 763 1123 C (38%) C 0.95 0.75-1.20 
5-HT2A receptor rs6311 (A-1438G) 13 (13q14-q21) synonymous 8 2678 2964 A (42%) G 1.16 1.01-1.33 
  rs6313 (T102C) 13 (13q14-q21) synonymous 45 9184 9892 T (47%) T 0.96 0.89-1.04 
  rs6314 (His452Tyr) 13 (13q14-q21) non-synonymous 5 2706 2878 T (9%) T 0.96 0.79-1.17 
5-HT6 receptor rs1805054 (C267T) 1 (1p36-p35) synonymous 4 530 519 T (25%) - 1.00 0.73-1.37 
SERT2 transporter 5-HTTVNTR 17 (17q11.1-q12) synonymous 12 2488 2927 10 (31%) 10 0.88 0.76-1.01 
  5-HTTLPR 17 (17q11.1-q12) synonymous 22 3720 4883 L (49%) L 1.04 0.97-1.11 
TPH13 enzyme rs1800532 (A218C) 11 (11p13.3-p14) synonymous 6 1239 1708 A (45%) C 1.25 1.08-1.44 
  rs1799913 (A779C) 11 (11p13.3-p14) synonymous 4 468 810 A (45%) C 0.92 0.77-1.11 
1. SNP = single nucleotide polymorphisms. 
2. SERT = serotonin transporter. 
3. TPH1 = tryptophan hydroxylase 1. 
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Not only schizophrenia itself, but also drug response or risk for developing side-effects such as tardive 
dyskinesia or weight gain, were the subject of pharmacogenetic studies of mutations in the serotonin 
system (for a comprehensive review see Arranz and de Leon, 2007). The aim of these studies was the 
development of genetic predictors for treatment response and side-effects to preselect and therefore 
improve antipsychotic treatment. The functional C-1019G variant of the 5-HT1A receptor was recently 
demonstrated to influence the response to atypical antipsychotics (Reynolds et al., 2006; Wang et al., 
2008; Mossner et al., 2009). These studies have consistently shown that carriers of the C-allele show 
greater improvement, especially in regard to negative symptoms. A number of studies reported 
significant associations between the linked 5-HT2A A-1438G and T102C receptor SNPs and response 
to atypical antipsychotics (mostly clozapine), but there are some discrepant results with respect to the 
risk-alleles for non-responding (Arranz et al., 1995; Arranz et al., 1998a; Arranz et al., 1998b; Joober 
et al., 1999; Yu et al., 2001; Lane et al., 2002; Hamdani et al., 2005; see also Arranz and de Leon, 
2007). In addition, there are several studies reporting that there is no association between the T102C 
substitution and the therapeutic response to clozapine and other antipsychotics (Masellis et al., 1995; 
Nothen et al., 1995; Jonsson et al., 1996; Malhotra et al., 1996; Lin et al., 1999). A more consistent 
picture comes from studies showing an influence of the functional His452Tyr polymorphism of the 5-
HT2A receptor on the clozapine response (Arranz et al., 1996; Masellis et al., 1998). Although several 
other studies failed to detect an association of this SNP and treatment response (Masellis et al., 1995; 
Nothen et al., 1995; Jonsson et al., 1996; Malhotra et al., 1996; Lin et al., 1999), a recent meta-
analysis showed a relatively strong association of the Tyr variant with poor response to clozapine 
(Arranz et al., 1998b). Mutations in the promoter (VNTR, T-759C, and G-995A), and coding region 
(Cys23Ser) of the 5-HT2C receptor have also been associated with clozapine response and 
improvement in negative symptoms (Sodhi et al., 1995; Arranz et al., 2000b; Reynolds et al., 2005). A 
further study was unable to detect an effect of the Cys23Ser SNP on treatment response  (Rietschel et 
al., 1997). In sum, the contribution of the variants to general drug response is relatively moderate, 
possibly indicating contribution to specific symptoms or side-effects that need further investigation 
(Arranz and de Leon, 2007). There are also some indices for an association of the 5-HT6 T-267C 
receptor variant with the response to treatment with clozapine and risperidone in Chinese patients (Yu 
et al., 1999; Lane et al., 2004), although this association has not been replicated in US patients 
(Masellis et al., 2001). Additionally, SERT polymorphisms have been investigated in respect to drug 
response but with exception of an initial positive finding (Arranz et al., 2000b) all further reports did 
not find significant associations (Arranz et al., 2000a; Tsai et al., 2000; Kaiser et al., 2001). Through 
combining data of gene variants previously associated with clozapine response, Arranz et al. (2000b) 
found that a combination of SNPs in the genes coding for 5-HT2A, 5-HT2C, histamine H2 receptors, and 
for the SERT resulted in the correct prediction of response in 76% of the cases. But so far this finding 
has not replicated (Schumacher et al., 2000). 
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The findings with respect to the association of 5-HT2A polymorphisms and tardive dykinesia are 
controversial (Basile et al., 2001; Segman et al., 2001; Tan et al., 2001; Lattuada et al., 2004; 
Deshpande et al., 2005; Lerer et al., 2005). The same is true for 5-HT2C polymorphisms (Rietschel et 
al., 1997; Zhang et al., 2002; Deshpande et al., 2005). Two recent studies reported promising results 
about a possible interaction of the 5-HT2A, 5-HT2C and D3 receptor genotype regarding the risk of 
developing tardive dyskinesia under antipsychotic treatment (Segman et al., 2000; Segman and Lerer, 
2002). 
The most significant results associate the 5-HT2C T-759C receptor variant with antipsychotic-induced 
weight gain (Arranz and de Leon, 2007). Although a number of studies failed to replicate this finding 
(Hong et al., 2001; Basile et al., 2002; Tsai et al., 2002; Theisen et al., 2004), the evidence for a 
protective effect of the T-allele is convincing (Reynolds et al., 2002b, 2003; Buckland et al., 2005; 
Ellingrod et al., 2005; Miller et al., 2005; Templeman et al., 2005). Given the strength of the reported 
associations, this could be a discovery with a useful clinical application as a predictor of drug-induced 
weight gain (Arranz and de Leon, 2007). 
In summary, genetic studies imply a critical role of mainly 5-HT1A and 5-HT2A receptors in the 
pathophysiology of schizophrenia and drug-response to antipsychotics.  
 
 
Serotonergic mechanisms of atypical antipsychotics 
 
5-HT2A receptor antagonism 
For a long time, one of the most important arguments for an involvement of the serotonin system in 
the etiology of schizophrenia was the serotonergic action of most of the so-called atypical 
antipsychotics. Due to the clinical experiences with the early antipsychotics, neuropharmacologists 
initially believed that extrapyramidal side effects (EPS) are an essential part of the antipsychotic 
effectiveness. The actually antiquated term “neuroleptics” (seize the neuron”) still refers to this 
association (Lidow, 2000). The reason for the positive correlation of antipsychotic effectiveness and 
EPS is that the antipsychotic potency of the early neuroleptics is proportional to their ability to block 
striatal D2 receptors, which is also the cause for EPS (Seeman et al., 1976). As a consequence, D2 
receptor blockade was proposed to be the principal mechanism of action of neuroleptics known until 
than (Creese et al., 1976), such as the phenothiazines chlorpromazine, perphenazine, fluphenazine, and 
thioridazine, the thioxanthenes thiothixene and flupentixol, and the butyrophenone haloperidol (which 
is still the most widely used neuroleptic drug). However, the dibenzodiazepine clozapine broke these 
rules, because its therapeutic effectiveness was not paired with notable EPS. Therefore, clozapine was 
described as an ‘atypical’ antipsychotic2. Unfortunately, the conditions for atypicality are not well 
                                                 
2 Second- or new-generation antipsychotics, multireceptor antipsychotics, or modern antipsychotics are often 
used (but not necessarily better) synonyms for atypical antipsychotics. Typical antipsychotics are also termed as 
classical or first-generation antipsychotics or neuroleptics, respectively. 
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defined. The narrowest definition is that atypical drugs produce lower EPS than typical drugs. 
However, in the last two decades several further prerequisites have been proposed: (1) atypical drugs 
should have a lower capacity to elevate prolactin levels and they should more strongly ameliorate 
negative and cognitive symptoms of schizophrenia compared to typical substances; (2) they should 
have a multi-receptor profile, higher in vivo selectivity for corticolimbic D2 receptors compared to 
striatal D2 receptors; (3) a higher D4 receptor affinity, and a serotonergic component or a higher 
affinity for 5-HT2A receptors than for D2 receptors (Meltzer, 1991, 1999; Blin, 1999; Lidow, 2000; 
Seeman, 2002). It becomes clear that, in the end, all these definitions are derived from the multiple 
mechanisms of action of clozapine (see above), and thus only clozapine itself matches all of these 
criteria, reducing the concept of atypicality to absurdity. 
Although clozapine is still the gold-standard regarding antipsychotic effectiveness, it has a not so rare 
(0.5-2%) and potentially life-threatening side effect: agranulocytosis (Buchanan, 1995). Therefore, 
scientists aimed to develop novel antipsychotics having the antipsychotic potency but not the 
dangerous side-effects of clozapine. Given that the superior efficacy of clozapine had been attributed 
to its high 5-HT2A receptor selectivity relative to the D2 receptor (Meltzer et al., 1989; Meltzer, 1991), 
the development of “balanced” 5-HT2A/D2 antagonists as potential antipsychotics was initiated in the 
late 1980s (Abi-Dargham and Krystal, 2000). This approach led to the discovery of novel 
antipsychotic substances such as risperidone, olanzapine, quetiapine, ziprasidone, and sertindole. All 
these compounds have higher affinity for the 5-HT2A receptor than for the D2 receptor, even if none of 
these show as high a D2/5-HT2A-binding ratio as clozapine (only the dibenzoxazepine amoxapine has a 
higher ratio than clozapine) (Seeman, 2002). As a consequence, Meltzer (1999) proposed that atypical 
antipsychotics with a high D2/5-HT2A-binding ratio are more effective against negative symptoms, 
show a stronger improvement of cognitive functions, and cause less EPS than typical antipsychotics. 
Several clinical trials have shown that atypical antipsychotics with strong 5-HT2A antagonism – first 
and foremost clozapine – improve negative symptoms more efficaciously than typical compounds 
(e.g., Kane et al., 1988; Marder and Meibach, 1994; Moller et al., 1995; Tollefson and Sanger, 1997). 
However, meta-analyses revealed rather moderate advantages of atypical antipsychotics in the 
treatment of negative symptoms (Carman et al., 1995; Leucht et al., 1999, 2009). Some scientists 
argued that these beneficial effects are only related to the improvement of secondary negative 
symptoms, which are correlated with the improvement of positive symptoms, depressive symptoms, 
EPS, or environmental deprivation, but that primary negative symptoms (also called as the ‘deficit 
syndrome’) are still unaffected by atypicals (Carpenter et al., 1995; Buchanan et al., 1998; Lidow, 
2000). Moreover, the view that a 5-HT2A receptor blockade is probably not necessary to improve 
negative symptoms is supported by a large meta-analyses showing that amisulpride – an atypical 
antipsychotic that is a selective D2/D3 receptor antagonist – has a comparable efficacy to clozapine 
with regard to negative symptoms (Leucht et al., 2002, 2009). 
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Cognitive dysfunctions constitute core symptoms of schizophrenia, and improvement of cognitive 
function is highly relevant for functional outcome such as social and occupational functioning (Green, 
1996; Liddle, 2000). Many studies have shown that, when compared to haloperidol, the atypicals 
clozapine, risperidone, and olanzapine differently improved functioning in several cognitive domains, 
including semantic memory, verbal learning and memory, sustained attention, and working memory 
(Kern et al., 1999; Meltzer and McGurk, 1999; Purdon et al., 2000; Bilder et al., 2002). However, 
most of these clinical trials did not use a control group or did not measure the control groups 
repeatedly. Meanwhile, recent data suggest that the measured cognitive improvements are only in the 
range of the expected test-retest enhancement (Goldberg et al., 2007; Quednow and Wagner, 
unpublished data). Additionally, the large (N=817) CATIE (Clinical Antipsychotic Trials of 
Intervention Effectiveness) schizophrenia trial funded by the National Institute of Mental Health 
(NIMH) has recently shown only small effects of several atypical drugs on neurocognitive composite 
scores after 2, 6, and 18 months of continued treatment (Keefe et al., 2007). After 2 months, treatment 
with the atypicals ziprasidone (z=0.12), olanzapine (0.13), quetiapine (0.18), risperidone (0.26), as 
well as the typical antipsychotic perphenazine (0.25), resulted in only small but significant 
neurocognitive improvements, with no significant differences between treatment groups. In contrast, 
after 18 months of treatment, neurocognitive enhancement was significantly greater in the 
perphenazine group than in the olanzapine and risperidone groups, despite the fact that perphenazine is 
a stronger D2 receptor that a 5-HT2A receptor blocker. This is in line with our previous data that 
treatment with the selective D2/D3 blocker amisulpride resulted in greater improvement of all cognitive 
domains (attention, executive function, working memory, and declarative memory) in schizophrenia 
patients compared to the clozapine-copy olanzapine (Wagner et al., 2005). These data strongly call the 
following two hypotheses into question: I.) that atypical antipsychotics improve cognitive deficits 
beyond simple test-retest effects, and II.) that 5-HT2A receptor blockade is necessary for the cognition 
enhancing effects of atypical substances.  
A recent meta-analysis showed that clozapine is still the antipsychotic drug with the lowest risk to 
produce EPS (measured by the amount of antiparkinsonian medication), followed by sertindole and 
olanzapine (Leucht et al., 2009). Several suggestions have been made to explain the low probability of 
EPS under clozapine treatment. The anticholinergic properties, the lack of ability to increase 
acetylcholine in the striatum, D1 and D4 receptor blockade, α1- or α2-adrenoreceptor antagonism, and 
the 5-HT2A receptor antagonism of clozapine have been proposed to reduce the risk of EPS. Data from 
animal models of schizophrenia as well as clinical data suggest that a high 5-HT2A receptor blockade 
in combination with a low D2 receptor blockade may help to avoid EPS, whereas the D1 receptor did 
not play a meaningful role (Meltzer, 1999; Roth and Meltzer, 2000). Given that many atypical 
compounds still induce EPS if higher doses are given, 5-HT2A blockade may not be sufficient for the 
reduction of EPS in the presence of complete or near complete D2 blockade. However, 5-HT2A 
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antagonism may reduce the risk for EPS when D2 receptors are not completely saturated (Abi-
Dargham and Krystal, 2000). 
Animal studies first indicated that selective 5-HT2A receptor antagonists lacking a dopaminergic 
component may have antipsychotic properties (Geyer et al., 2001). The selective 5-HT2A receptor 
blocker MDL 100,907 was the first compound whose antipsychotic activity was exclusively predicted 
by preclinical animal models (Varty et al., 1999). In a subsequent clinical trial MDL 100,907 was not 
sufficiently more effective than haloperidol in the treatment of schizophrenia, although it was more 
effective than placebo in reducing psychotic symptoms (de Paulis, 2001). Nevertheless, there is no 
efficacious and approved antipsychotic without a dopaminergic mechanism of action so far. Moreover, 
the mechanism underlying the therapeutic superiority of clozapine is still unclear. One alternative 
hypothesis for atypicality focused on the special kinetics of interaction with the D2 receptor displayed 
by atypical drugs and, therefore, negating the role of 5-HT2A receptors (Kapur and Seeman, 2001). 
Data reported in Seeman (2002) are interpreted to suggest that most of the atypical drugs dissociate 
much faster from D2 receptors than do typical compounds. The dibenzapines clozapine and quetiapine 
and the benzamides amisulpride and remoxipride show the fastest dissociation from the D2 receptor. 
Seeman (2002) concluded that transient occupation of D2 receptors allows relatively normal dopamine 
neurotransmission, which is likely to be a prerequisite for normal prolactin levels, intact cognition and 
avoidance of EPS. This “fast-off-D2” theory was strongly criticized because it applies only to 
clozapine and quetiapine and is inconsistent with the relatively slow dissociation of several atypicals, 
including olanzapine, risperidone, ziprasidone, and sertindole (Meltzer et al., 2003). However, so far 
there is no other theory that explains the high antipsychotic efficacy of both clozapine and 
amisulpride.  
Schizophrenia is most likely not a homogeneous entity of an illness but a cluster of diverse 
schizophreniform diseases with different pathogeneses. Thus, some patients may have more benefit of 
a serotonergic compound than others. However, to date there are no criteria to safely predict the 
response to treatment with either antipsychotic. 
 
Role of other 5-HT receptors 
Most of the atypical antipsychotics have affinities for multiple 5-HT receptors (see Table 4). We will 
briefly discuss the interaction of antipsychotics with 5-HT1A, 5-HT2C, 5-HT3, 5-HT4, 5-HT6, and 5-HT7 
receptors. 
Numerous antipsychotics display activity at human 5-HT1A receptors: Aripiprazole, clozapine, 
quetiapine, and ziprasidone display marked affinity and act as agonists or partial agonists, whereas 
risperidone and sertindole display low affinity and act as antagonists. Moreover, several of the typical 
compounds, including haloperidol and chlorpromazine, also exhibit relatively low affinity and 
antagonistic properties at 5-HT1A receptors (Newman-Tancredi et al., 1998; Shapiro et al., 2003). 
Thus, a specific 5-HT1A action is likely not necessary for antipsychotic activity. However, a 5-HT1A 
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agonist activity was proposed to enhance memory and cognition in schizophrenia because it was 
shown that I.) 5-HT1A receptors are concentrated in brain regions thought to mediate several cognitive 
functions (e.g. hippocampus, thalamus, cingulate cortex and PFC) (Roth et al., 2004); and II.) 
clozapine increases dopamine release in the PFC via its 5-HT1A agonism (Rollema et al., 1997). In 
support of this hypothesis, Sumiyoshi et al. (Sumiyoshi et al., 2001a, 2001b) reported that chronic 
administration of the selective 5-HT1A receptor agonist tandospirone as a co-therapy with typical 
antipsychotics enhance verbal memory and executive functions in schizophrenia patients. In contrast, 
chronic co-administration of the 5-HT1A receptor partial agonist buspirone with atypical antipsychotics 
improved psychomotor speed but not memory or executive function in schizophrenia patients 
(Sumiyoshi et al., 2007). On the other hand, tandospirone exerted negative effects on memory function 
in demented patients (Yasuno et al., 2003), and the potent 5-HT1A agonist NAE-086 induced 
hallucinations and nightmares in healthy volunteers after repeated doses (Renyi et al., 2001). Thus, 
augmentation with a 5-HT1A partial agonist for cognitive enhancement in schizophrenia seems only to 
be effective in combination with antipsychotics that lack 5-HT1A activity. Contrarily, atypical 
antipsychotics with a 5-HT1A agonistic action should not be combined with tandospirone or buspirone 
because this may worsen psychotic symptoms and has no additional effects on cognition (Roth et al., 
2004). 
In addition, clozapine has higher affinity for the 5-HT2C receptor than for the 5-HT2A receptor. Animal 
studies first suggested that activation of 5-HT2C receptors is inhibitory, while activation of 5-HT2A 
receptors is stimulatory (Martin et al., 1997, 1998). This led to the conclusion that 5-HT2C receptor 
agonists might be antipsychotic (Abi-Dargham and Krystal, 2000). Newer data have shown that 5-
HT2C receptor antagonists can directly increase dopamine release in the nucleus accumbens (NAC) 
and the PFC (Di Matteo et al., 1998), while 5-HT2C receptor agonists markedly decrease dopamine and 
noradrenalin levels in the frontal cortex of rats (Millan et al., 1998). Administration of the 5-HT2C/2A 
agonist m-CPP caused deterioration of positive psychotic symptoms in schizophrenia, an effect that 
could be prevented by the 5-HT2C/2A blocker ritanserin (Abi-Saab et al., 2002). Moreover, ritanserin in 
combination with risperidone showed significant superiority over risperidone alone in decreasing 
negative symptoms in schizophrenia patients (Akhondzadeh et al., 2008). These results suggest that 5-
HT2C blockade may actually have beneficial effects on positive, negative, and cognitive symptoms in 
schizophrenia (Meltzer et al., 2003). In contrast, earlier work demonstrated that affinity to the 5-HT2C 
receptor did not distinguish typical from atypical antipsychotics (Roth et al., 1992) and Meltzer et al. 
(2003) concluded that the high 5-HT2C receptor affinity of some atypical substances (e.g. clozapine, 
olanzapine, sertindole) roughly corresponds with their potential to produce weight gain rather than 
with potential antipsychotic activity. However, some clinical data did suggest that augmentation with 
the 5-HT2C/2A antagonists ritanserin and mianserin may have some beneficial effects especially on 
negative and cognitive symptoms in schizophrenia (Lieberman et al., 1998; Meltzer et al., 2003; 
Akhondzadeh et al., 2008). 
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Table 4: Affinities of selected antipsychotic drugs for 5-HT receptors expressed as pKi (the negative logarithm to base 10 of the equilibrium dissociation 
constant, Ki, in molar concentration units). Higher values imply a higher affinity. No value is shown if no data were available or if the pKi was below 3. All data 
were drawn from the IUPHAR database (Harmar et al., 2009; www.iuphar-db.org). 
 
Drug 5-HT1A 5-HT1B 5-HT1D 5-HT1E 5-HT1F 5-HT2A 5-HT2B 5-HT2C 5-HT5A 5-HT6 5-HT7 
Aripiprazol 8.2ag 6.1ag 7.2ag   7.5 – 8.1ag  7.6ag    
Chlorpromazine 6.2ant     8.1iag  7.6 – 8.2ant  7.7 – 7.8iag 7.6iag 
Clozapine 6.8 – 6.9ag 6.2ag 6.4ag 6.4ag 6.9ag 7.6 – 9.0iag 8.0 – 8.8ant 7.4 – 8.7iag 6.0 – 6.5ant 7.8 – 8.1iag 7.2 – 7.8iag 
Haloperidol 5.7 – 5.8ant  6.6ant   6.7 – 7.3ant 5.8 – 6.4ant    6.3 – 6.6ant 
Olanzapine 5.6 – 5.8ag 6.3ag 6.2ag 5.7ag 6.5ag 8.6 – 8.7ant  8.1 – 8.2iag  8iag 6.5ant 
Perphenazine      8.2ant  6.9ant  7.1iag 7.2iag 
Quetiapine 6.5 – 6.6ag  5.7ag 5.9ag 5.6ag 6.4 – 7.0      
Risperidone 6.4 – 6.5ant 6.6 – 7.0ant 7.8 – 8.0ant 5.9ant 5.9ant 9.3 – 10.0iag  7.5 – 7.6iag  5.6ant 8.3 – 8.7iag 
Sertindole 6.4 – 6.6ant 7ant 7.2ant 6.4ant 6.4ant 9.2 – 9.4ant  9.0 – 9.2iag    
Ziprasidone 7.9 – 8.9pag 8.3ag 9ag 6.4ag   8.8 – 9.5ant   7.9 – 8.4iag     8.4iag 
            
ag = agonist            
ant = antagonist            
pag =partial agonist            
iag = inverse agonist            
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5-HT3 receptor antagonists have also been investigated as potential antipsychotics because clozapine 
has a moderate affinity for this receptor and preclinical animal studies indicated possible antipsychotic 
efficacy (Lieberman et al., 1998). Although an open-label and uncontrolled clinical trial demonstrated 
a moderate antipsychotic activity of the selective 5-HT3 receptor antagonist ondansetron (DeVeaugh-
Geiss et al., 1992), these results could not be replicated in a double-blind study (Gaster and King, 
1997). Also, the 5-HT3 antagonist zacopride was not effective in the treatment of schizophrenia 
(Newcomer et al., 1992), suggesting that the 5-HT3 receptor is not a promising drug target in the 
treatment of schizophrenia. 
Given that 5-HT4 receptors modulate acetylcholine and GABA release and that 5-HT4 receptors are 
found in high densities in the frontal cortex and the hippocampus, it was suggested that a modification 
of 5-HT4 receptor activity could be helpful in improving cognition in schizophrenia. Several animal 
studies support this assumption, but studies in healthy human volunteers and schizophrenia patients 
are lacking so far (Roth et al., 2004; Gray and Roth, 2007). Since atypical antipsychotic drugs are 
devoid of major 5-HT4 receptor actions, Roth et al. (2004) recommended that a 5-HT4 partial agonist 
would be potentially beneficial as add-on therapy for improving cognition in schizophrenia. 
On the basis of animal studies, the 5HT6 receptor was suggested to be a promising drug target to 
specifically improve cognition in schizophrenia as well (Meltzer et al., 2003; Roth et al., 2004; Gray 
and Roth, 2007). The 5-HT6-selective antagonist SB-271046 is currently undergoing preclinical testing 
as a cognitive enhancer in schizophrenia (Hatcher et al., 2005; Marcos et al., 2008; Da Silva Costa et 
al., 2009). However, several typical (e.g., chlorpromazine, fluphenazine) and atypical antipsychotics 
(e.g. clozapine, olanzapine, ziprasidone and quetiapine) have high affinity for the 5-HT6 receptor, 
making it unlikely that addition of a 5-HT6 antagonistic drug would further improve cognition in 
schizophrenia patients treated with these antipsychotics (Roth et al., 1994; Roth et al., 2004). 
Moreover, both 5-HT6 agonist and antagonists have shown pro-cognitive properties in preclinical 
animal studies, but an explanation for these paradoxical effects is currently missing (Fone, 2008). 
Thus, further studies are needed to further understand the role of the 5-HT6 receptor in the modulation 
of cognition and to develop 5-HT6 antagonist compounds for the treatment of cognitive deficits in 
schizophrenia. 
Both clozapine and risperidone, as well as the typical drugs chlorpromazine, fluphenazine, and 
pimozide have high affinity for the 5-HT7 receptor (Roth et al., 1994); this suggests that a 5-HT7 
action is not a feature of atypicality (Abi-Dargham and Krystal, 2000). Evidence primarily drawn from 
knock-out studies in mice indicate that the 5-HT7 receptor plays an important role in hippocampus-
dependent functions, including learning and memory (Gray and Roth, 2007). These data warrant 
further investigation into the potential use of 5-HT7 receptor antagonist compounds in the treatment of 
memory dysfunction in schizophrenia (Gray and Roth, 2007). 
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Antipsychotic drug action and serotonin receptor occupancy 
Most of the molecular imaging studies investigating the role of receptor occupancy in antipsychotic 
activity by PET or SPECT have traditionally focused on the dopamine system. Here it was 
consistently shown that typical antipsychotics usually produce higher striatal D2 receptor occupancy 
rates (>70%) than atypical antipsychotics (<70%) at mean therapeutic doses (Lieberman et al., 1998; 
Kasper et al., 1999; Weinberger and Laruelle, 2002). Given that the atypicals clozapine and quetiapine 
display the lowest rates of D2 occupancy (20-67%) at clinically effective doses and that most of the 
studies could not demonstrate a linear correlation between striatal D2 binding and therapeutic efficacy, 
striatal D2 receptor occupancy rates alone can not sufficiently explain antipsychotic activity (Kasper et 
al., 1999; Weinberger and Laruelle, 2002). On the contrary, several studies consistently found a clear 
correlation between EPS and striatal D2 receptor occupancy, indicating a high likelihood of EPS when 
D2 occupancy exceeds a threshold of 80% (Kasper et al., 1999; Weinberger and Laruelle, 2002; 
Zipursky et al., 2007). Since at least 50-60% D2 receptor occupancy is required to observe rapid 
clinical response with typical antipsychotics such as haloperidol, an optimal antipsychotic dose range 
resulting in 70-80% D2 occupancy was suggested (Nordstrom et al., 1993; Nyberg et al., 1999; Kapur 
et al., 2000). However, this rule does not apply to clozapine and quetiapine. 
In line with the in vivo data (see above), most of the atypical drugs display higher 5-HT2A than D2 
occupancy rates when dual-tracer approaches are used (Kapur et al., 1998; Nyberg et al., 1999; 
Gefvert et al., 2001; Mamo et al., 2004). But although it was suggested that the predominant 5-HT2A 
receptor antagonism of atypical drugs protects against EPS (Meltzer, 1999), even atypical substances 
such as olanzapine or risperidone cause EPS when given in higher doses that lead to D2 receptor 
occupancy of more than 80% (Kapur et al., 1998; Nyberg et al., 1999). Thus, occupancy of 5-HT2A 
receptors does not confer protection against EPS, because the threshold of D2 receptor occupancy 
associated with EPS is not markedly reduced for atypical substances with a balanced 5-HT2A/D2 
receptor profile (Weinberger and Laruelle, 2002). Compared to the other atypicals, aripiprazole is an 
interesting exception regarding D2, 5-HT2A, and 5-HT1A receptor occupancy. A recent study has shown 
that aripiprazole exhibits very high striatal D2 occupancy (81-94%), a lower occupancy of frontal and 
temporal 5-HT2A receptors (31-84%), and even lower occupancy at frontal and temporal 5-HT1A 
receptors (-2-44%) at doses between 10 to 30 mg in schizophrenia patients. EPS was seen only in two 
of four subjects with D2 occupancies exceeding 90% (Mamo et al., 2007). In accordance with the 
study of Bantick et al. (2004), who showed that clozapine did not occupy the 5-HT1A receptor at 
clinical doses, these data do not support an important role of the 5-HT1A receptor regarding 
antipsychotic activity. In sum, molecular imaging studies do not support the view that the 5-HT2A or 5-
HT1A mechanism of several atypical drugs contributes significantly to their clinical superiority. 
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Serotonergic challenge studies 
Given that the release of several hormones, such as cortisol, prolactin, and growth hormone (GH), is 
under monoaminergic control, the neuroendocrine challenge paradigm is suitable to investigate the 
functional state of central monoaminergic systems. In a hypersensitive system, stimulation of 5-HT 
receptors will induce augmented hormonal release, whereas in a hypoactive system, increased release 
would be expected. If 5-HT receptors are antagonized, the reverse results are anticipated (Murphy et 
al., 1986). 
Early neuroendocrine challenge studies investigating small samples of schizophrenia patients and 
employing the 5-HT precursors tryptophan and 5-hydroxytryptophan (5-HTP) reported inconsistent 
results. Two studies reported an increased prolactin response and a blunted GH release (Cowen et al., 
1985; Kolakowska et al., 1987). One study found decreased prolactin responses and decreased GH 
response only in long-term haloperidol-treated patients, whereas short-term treated patients did not 
differ from controls in both measures (Hoshino et al., 1985). However, precursor effects are relatively 
muted because of their ‘upstream’ (and therefore secondary) actions on synaptic function making 
these studies hard to interpret (Breier, 1995). 
Challenge studies with the serotonin releaser fenfluramine (racemate or d-form) provided some 
conflicting results as well. Whereas an initial study reported a decreased prolactin release in chronic 
patients (Lerer et al., 1988), two later studies found prolactin hyperresponsivity in drug-free patients 
(Abel et al., 1996; Monteleone et al., 1999). However, in the study of Monteleone et al. (1999) the 
elevated prolactin response was restricted to patients who were refractory to typical neuroleptics. In 
line with that, Mohr et al. (1998) reported that a higher prolactin response to d-fenfluramine, and 
therefore a higher responsiveness of the 5-HT system, was associated with poorer treatment response 
to haloperidol in unmedicated first-episode patients. Additionally, Sharma et al. (1999) found that that 
a higher prolactin response to dl-fenfluramine was correlated with more negative symptoms. These 
studies also varied with regard to psychotic symptom provocation after fenfluramine: some reported 
no changes, while others described exacerbation of positive symptoms. 
The serotonin and noradrenaline reuptake inhibitor clomipramine, which also acts as a 5-HT2 receptor 
antagonist, provoked an increased prolactin response in drug-naïve schizophrenia patients, an effect 
that was positively correlated with duration of illness and negatively correlated with treatment 
response (Angelopoulos et al., 2002). However, another study did not find changes in the prolactin 
release after clomipramine in patients treated with typical antipsychotics (Markianos et al., 2001). 
The drug m-chlorophenylpiperazine (m-CPP) preferentially acts as a partial agonist at 5-HT2C 
receptors and as an antagonist at 5-HT2A receptors, but also binds also to several other 5-HT receptor 
subtypes (Kahn and Wetzler, 1991). m-CPP increases anxiety, body temperature, and plasma levels of 
prolactin, cortisol, GH, and ACTH, but does not provoke psychotic symptoms in healthy human 
volunteers (Breier, 1995). Schizophrenia patients show either blunted (Iqbal et al., 1991; Maes and 
Meltzer, 1996) or normal prolactin response to m-CPP (Kahn et al., 1992; Krystal et al., 1993). 
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Moreover, m-CPP has been reported to exacerbate (Iqbal et al., 1991; Krystal et al., 1993; Abi-Saab et 
al., 2002), reduce (Kahn et al., 1992), or have no effect on psychotic symptoms (Breier et al., 1993; 
Owen et al., 1993; Koreen et al., 1997). Clozapine has been reported to block the symptom-worsening 
and hormone-releasing effects of m-CPP, which was attributed to 5-HT2C antagonistic effects of 
clozapine (Breier et al., 1993; Kahn et al., 1993b; Krystal et al., 1993; Owen et al., 1993). Similar 
effects were shown for olanzapine (Abi-Saab et al., 2002) and the 5-HT2 antagonist ritanserin 
(Scheepers et al., 2001a). 
In general, the contradictory results across the different serotonergic challenge studies point to 
heterogeneity in central serotonergic sensitivity within different subpopulations of schizophrenia 
patients. This assumption is also supported by the consistent observation that a hypersensitive 5-HT 
system is associated with poor treatment response to mostly typical antipsychotics. Serotonergic 
challenge studies might therefore be useful for tailoring individual antipsychotic pharmacotherapy. 
 
 
Serotonin metabolites in the cerebrospinal fluid 
Many studies have measured monoamine metabolite concentrations in the cerebrospinal fluid (CSF) of 
schizophrenia patients in order to investigate central 5-HT and dopamine turnover. Most of the early 
studies did not find changes in the CSF concentration of the major 5-HT metabolite 5-HIAA, but some 
reported decreased 5-HIAA CSF levels in schizophrenia (for review and references see Bleich et al., 
1991). A more recent meta-analysis and a recent study with a large sample of schizophrenia patients 
supported the view that mean 5-HIAA concentrations in the CSF are generally relatively unaltered in 
schizophrenia patients (Tuckwell and Koziol, 1996; Wieselgren and Lindstrom, 1998). In contrast, 
another meta-analysis indicated that CSF levels of the main metabolite of dopamine, homovanillic 
acid (HVA), are lowered in schizophrenia patients (Tuckwell and Koziol, 1993); this finding was 
confirmed by a more recent study investigating 90 schizophrenia patients and 47 healthy controls 
(Wieselgren and Lindstrom, 1998). Studies linking specific characteristics of the illness with 5-HIAA 
CSF levels have shown that low 5-HIAA concentrations are associated with advanced brain atrophy 
(Nyback et al., 1983; Potkin et al., 1983; Jennings et al., 1985; Losonczy et al., 1986), more prominent 
negative symptoms (Pickar et al., 1986; Csernansky et al., 1990), and failure to activate the PFC 
during the Wisconsin Card Sorting Test (Weinberger et al., 1988). But all of these measure have been 
found to be associated with decreased HVA CSF levels as well (ibid.; Scheepers et al., 2001b). 
However, one of the best replicated findings in biological psychiatry is the strong intercorrelation of 
monoamine metabolites in the CSF, which possibly could be explained by similar transport 
mechanisms of all monoamines (Hsiao et al., 1993). This idea has led to the approach to calculate 
HVA/5-HIAA concentration ratios to investigate the relation of serotonergic and dopaminergic 
activity in schizophrenia (Hsiao et al., 1993). Lewine et al. (1991) demonstrated for example that the 
HVA/5-HIAA ratio was a better predictor of the extent of brain atrophy than HVA or 5-HIAA CSF 
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levels alone (see also Nyback et al., 1983). Additionally, while 5-HIAA and HVA levels alone could 
not predict treatment outcome, a low HVA/5-HIAA CSF ratio was significantly associated with better 
response to clozapine and typical antipsychotics in several studies (Pickar et al., 1992; Kahn et al., 
1993a; Risch and Lewine, 1993; Szymanski et al., 1993; Lieberman et al., 1994; Risch, 1995). These 
results suggested that the antipsychotic effect is associated with changing dopamine function relative 
to 5-HT function, rather that changing dopamine or 5-HT function per se (Scheepers et al., 2001b). 
However, at least two studies failed to find a predictive value of the HVA/5-HIAA CSF ratios 
regarding treatment response to olanzapine, clozapine, or haloperidol treatment (Jacobsen et al., 1997; 
Scheepers et al., 2001b), while one study reported a worse long-term outcome in patients with a low 
HVA/5-HIAA CSF ratio (Wieselgren and Lindstrom, 1998). These discrepancies may be explained 
due to differences in patient populations, duration of treatment, method of analysis, or criteria of 
response. 
Surprisingly, several investigations demonstrated that neither typical nor atypical antipsychotics 
changed 5-HIAA CSF levels in the course of treatment, although many of these substances strongly 
affect the 5-HT system (van Kammen et al., 1986; Kahn et al., 1994; Jacobsen et al., 1997; Wieselgren 
and Lindstrom, 1998; Scheepers et al., 2001b). These results put the idea somewhat into question that 
5-HIAA CSF concentrations are a valid marker of the central 5-HT turnover. Moreover, it was 
suggested that 5-HIAA concentrations may not mirror 5-HT metabolism in the whole brain but rather 
reflect turnover in specific brain regions such as frontal cortices and the striatum (Scheepers et al., 
2001b). On the contrary, typical antipsychotics seem to consistently elevate HVA CSF levels and 
HVA/5-HIAA CSF ratios, while atypical substances did not (Hsiao et al., 1993; Kahn et al., 1993a; 
Wieselgren and Lindstrom, 1998; Scheepers et al., 2001b). 
In sum, investigations on 5-HT metabolite levels in the CSF in schizophrenia are hard to interpret 
because it is not clear what the specific neuronal substrate of 5-HIAA CSF levels is. However, there is 
some consistency in the data showing that at least a subpopulation of patients display changes in 
global 5-HT and dopamine turnover, and these patients may respond differentially to antipsychotics 
that other subpopulations. 
 
 
Platelet studies 
Human blood platelets have been proposed as a peripheral model of central 5-HT function because 
platelets are neuroectodermal derivatives that share several biochemical and morphological 
characteristics with 5-HT synapses (Bleich et al., 1991). 
Most of the studies investigating platelet or whole blood 5-HT concentrations in schizophrenia 
patients found elevated values, although there are also some contradictory results (for review see 
Bleich et al., 1991; and Iqbal and van Praag, 1995). The increase in peripheral 5-HT concentrations 
reported in the early studies was apparently not an artifact of medication, as no in vivo effect of 
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antipsychotics on platelet 5-HT could be demonstrated (Bleich et al., 1991). On the contrary, 
accumulating evidence suggests that treatment with clozapine and other atypical and typical 
antipsychotics increases 5-HT plasma levels in schizophrenia patients (Joseph et al., 1977; Schulz et 
al., 1997; Fleischhaker et al., 1998; van der Heijden et al., 2004; Ertugrul et al., 2007). These findings 
suggest that antipsychotics still have an impact on peripheral 5-HT concentrations and indicate that 
medication may have indeed influenced previous results. 
The findings on platelet 5-HT uptake are less consistent. The amount of studies reporting reduced or 
unchanged platelet 5-HT uptake is more or less equal (for review see Bleich et al., 1991; and Iqbal and 
van Praag, 1995). However, Arora and Meltzer (1983) have convincingly demonstrated that a two 
week treatment with chlorpromazine significantly decreased platelet 5-HT uptake in schizophrenia 
patients and healthy controls. Thus, previous findings of reduced platelet 5-HT uptake in 
schizophrenia patients are likely explained by acute or residual antipsychotic treatment effects. 
Moreover, several studies investigating [3H]imipramine binding sites on platelets, which have been 
suggested as another measure of 5-HT uptake or transport, predominantly yielded no differences 
between normals and schizophrenia patients (for review see Bleich et al., 1991; and Iqbal and van 
Praag, 1995). 
Platelet 5-HT2A receptors are identical with brain 5-HT2A receptors in terms of their pharmacological 
properties (Ostrowitzki et al., 1993). Although Arora and Meltzer (1983) detected a increased number 
of 5-HT2A receptors on platelets from suicidal schizophrenia patients, a newer study reported increased 
platelet 5-HT2A receptor density in chronic, medication-free patients with schizophrenia (Arranz et al., 
2003). Given that treatment with risperidone strongly increased platelet 5-HT2A receptor density, 
Arranz et al. (2003) concluded that the increased platelet 5-HT2A receptor density in their drug-free 
sample was a residual drug effect caused by previous antipsychotic treatment. Additionally, these 
authors reported recently that low baseline platelet 5-HT2A receptor levels may predict clinical 
response to olanzapine in a group of antipsychotic-naïve schizophrenia patients (Arranz et al., 2007). 
The activity of platelet monoamine oxidase (MAO) activity has also been studied in schizophrenia, 
demonstrating results similar to platelet 5-HT2A receptor density. Although there are some indications 
of decreased platelet MAO activity at least in some subgroups of schizophrenia patients (Zureick and 
Meltzer, 1988), it could not be excluded that this effect is primarily caused by antipsychotic treatment 
(DeLisi et al., 1981; Ohuoha et al., 1993; Ertugrul et al., 2007). 
It should be noted that the changes of serotonergic markers found in platelets are largely in the 
opposite direction than the alterations that were found in more centrally relevant 5-HT measures in 
schizophrenia patients (decreased 5-HT in CSF and brain tissue vs. increased 5-HT in blood and 
platelets; decreased 5-HT receptors in several brain regions vs. increased 5-HT2A receptor density in 
platelets, and so on). In addition, treatment with antipsychotics also had mostly opposite effects on 
platelet and brain 5-HT markers, respectively. These facts suggest that platelets are not an ideal model 
for brain 5-HT function (Roth and Meltzer, 2000). 
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Neurotrophic role of serotonin in the developmental disorder schizophrenia 
As reviewed by Whitaker-Azmitia in this volume, serotonin plays a major role at several stages of 
neuroplasticity. During embryogenesis the serotonin system is one of the first neurotransmitter 
systems that innervates brain structures and demonstrates functional activity. In this phase, serotonin 
acts as a growth factor that influences neuronal and glial morphology, and connectivity. Some of these 
effects are direct, whereas some others are mediated by the interaction with further chemical 
messengers (such as brain-derived neurotrophic factor [BDNF] or S100β) and other neurotransmitter 
systems (such as dopamine, GABA, and glutamate). But postnatal serotonin also influences the 
formation and degradation of synapses and axon terminals, indicating that serotonin is important not 
only for neuronal development but also for the preservation and maintenance of normal function in the 
adult brain (see also Sodhi and Sanders-Bush, 2004). 
Accumulating evidence from several domains suggests that schizophrenia could be a 
neurodevelopmental disorder that is – at least in part – caused by aberrant early brain development: I.) 
Many schizophrenia patients exhibit delayed developmental milestones in childhood, including 
cognitive, motor, and behavioral abnormalities, which indicates abnormal brain function prior to 
diagnosis of schizophrenia, II.) Obstetric complications and prenatal infections increase the risk for 
schizophrenia, III.) Post-mortem studies did not find indicators for neurodegenerative processes such 
as gliosis or loss of neurons in the brain of schizophrenia patients, and IV.) several anatomical and 
functional disruptions are associated with exacerbation of schizophrenia in adulthood and these 
disruptions can be simulated in developmental animal models (Marenco and Weinberger, 2000; 
Miyamoto et al., 2003). As suggested by Murray et al. (1992), aberrant developmental processes may 
play a major role, especially in the congenital subform of schizophrenia that shows a gradual increase 
in behavioral disturbances until the disorder is diagnosed in adolescence or early adulthood. Maynard 
and colleagues (2001) have proposed a two-hit hypothesis of schizophrenia. According to their 
suggestion a lesion occurring in early neurodevelopment (first hit), caused by a genetic load or adverse 
embryonic and perinatal events, in combination with a second hit, arising from hormonal events, 
excitotoxicity, psychosocial stress, or oxygen radical formation, may cause schizophrenia. 
Immunocytochemical and ultrastructural post-mortem studies have demonstrated neurocellular 
alterations in schizophrenia, such as decreased neuronal size, increased cellular packing density, fewer 
dendritic spines and synapses, and distortions in neuronal orientation (for review see Arnold, 1999). 
The abnormalities in the cytoarchitecture, such as neuronal disarray, heterotopias, and malpositioning, 
indicate disruption of proliferation or migration at the gestational period (Miyamoto et al., 2003). In 
accordance, it was consistently shown that the expression of reelin, a glycoprotein that regulates 
neuronal migration, is strongly decreased in schizophrenia patients (Impagnatiello et al., 1998; 
Guidotti et al., 2000). Moreover, anatomical studies found enlargements of the lateral and third 
ventricles in conjunction with a decrease in cortical volume, especially within the hippocampal 
formation and the amygdala; additionally, subcortical structures appear to be reduced in size, 
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including the thalamus and striatum (for review see Sodhi and Sanders-Bush, 2004). It is unlikely that 
these macrostructural alterations are simply caused by neurodegenerative processes because some of 
these alterations have been shown also at a prodromal state of schizophrenia (Wood et al., 2003; 
Morey et al., 2005; Jessen et al., 2006), and post-mortem studies did not found gliosis and neuronal 
cell loss. Thus, these anatomical and cytoarchitectual changes are likely to arise during brain 
maturation. 
Several lines of evidence suggest that abnormalities in brain development may contribute to the 
pathogenesis of schizophrenia in a subset of patients. Moreover, we know that serotonin plays an 
important role in neurogenesis and neuronal plasticity. However, future studies will have to determine 
whether genetic or early developmental insults could alter the serotonin system in a manner that leads 
to sustained neuronal changes during brain development, which consequently induces the symptoms 
of schizophrenia.  
 
 
Serotonin-glutamate interactions 
NMDA antagonists such as phencyclidine (PCP) and ketamine produce effects in humans that closely 
mimic the symptoms of schizophrenia (Javitt and Zukin, 1991; Krystal et al., 1994). Microdialysis 
studies have demonstrated that ketamine and PCP increase glutamate outflow in PFC (Moghaddam et 
al., 1997; Adams and Moghaddam, 1998). Potentially related to this effect is evidence that increases in 
glutamatergic activity may contribute to the psychotomimetic and behavioral effects of these drugs. 
Indeed, diminution of PCP-induced glutamate release by activation of metabotropic glutamate 2/3 
(mGlu2/3) receptors attenuates the effects of PCP on locomotor activity and stereotypy (Moghaddam 
and Adams, 1998). Other agents that decrease glutamate release also reduce the behavioral effects of 
PCP and ketamine (Anand et al., 2000; Idris et al., 2005). In each of these cases, the actions of the 
released glutamate would presumably be on non-NMDA glutamate receptors, either AMPA, kainate, 
or metabotropic, since PCP and ketamine block NMDA receptor functions. The involvement of 
glutamate release in the psychotomimetic effects of NMDA antagonists is consistent with the 
hypothesis that dysfunction of glutamatergic systems underlies the psychopathology of schizophrenia 
(Javitt and Zukin, 1991; Halberstadt, 1995; Jentsch and Roth, 1999). 
Electrophysiological evidence demonstrates that LSD and other serotonergic hallucinogens can 
modulate cellular responses to glutamate (Rahman and Neuman, 1993; Arvanov et al., 1999). Recent 
studies indicate that hallucinogens increase the release of glutamate in neocortex (Scruggs et al., 2003; 
Muschamp et al., 2004). Activation of 5-HT2A receptors by 5-HT and the hallucinogen 2,5-dimethoxy-
4-iodoamphetamine (DOI) produces an enhancement of the frequency and amplitude of spontaneous 
excitatory postsynaptic potentials/currents (EPSPs/EPSCs) in most layer V pyramidal cells of PFC 
(Aghajanian and Marek, 1997; Lambe et al., 2000; Klodzinska et al., 2002; Benneyworth et al., 2007); 
this effect is mediated by increased glutamate efflux and subsequent activation of AMPA receptors 
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(Zhang and Marek, 2008). There is also evidence that 5-HT- and DOI-induced EPSCs are suppressed 
by activation of mGlu2/3 receptors, and are augmented by mGlu2/3 receptor blockade (Marek et al., 
2000; Klodzinska et al., 2002; Benneyworth et al., 2007). Although it is generally accepted that 5-
HT2A receptor activation increases the terminal release of glutamate in PFC, there has been some 
controversy regarding the source of these glutamatergic terminals. Based on evidence that lesions of 
the medial thalamus attenuate 5-HT-induced EPSCs, Marek and colleagues have argued that 
thalamocortical afferents are involved (Marek et al., 2001). However, Béïque et al. (2007) recently 
identified a subpopulation of pyramidal cells in the deep layers of PFC that are excited by 5-HT2A 
receptor activation, indicating that the spontaneous EPSCs evoked by 5-HT may be a product of PFC 
recurrent network activity. 
As was found with PCP, the behavioral effects of serotonergic hallucinogens are attenuated by 
activation of mGlu2/3 receptors. The ability of DOI to induce the head twitch response in mice and rats 
is suppressed by the selective mGlu2/3 agonists LY354740 and LY379268; conversely, the selective 
mGlu2/3 antagonist LY341495 enhances the frequency of DOI-induced head twitch (Gewirtz and 
Marek, 2000; Klodzinska et al., 2002). Likewise, the mGlu2 positive allosteric modulator biphenyl-
indanone A inhibits the head twitch response induced by the hallucinogen (-)-2,5-dimethoxy-4-
bromoamphetamine (DOB) (Benneyworth et al., 2007). It has also been shown that the discriminative 
stimulus effects of LSD are potentiated by LY341495 and partially antagonized by LY379268 (Winter 
et al., 2004). The ability of mGlu2/3 receptor ligands to alter the behavioral response to DOI, DOB, and 
LSD indicates that the behavioral effects of hallucinogens are linked to their ability to increase 
glutamate release.  
Taken together, the aforementioned findings demonstrate that NMDA receptor antagonists and 
serotonergic hallucinogens increase glutamate release, and it has been suggested that the glutamatergic 
system may represent a common final pathway for their psychotomimetic effects (Vollenweider and 
Geyer, 2001). This view is consistent with the fact that both ketamine and psilocybin produce 
metabolic hyperfrontality (Vollenweider et al., 1997a, 1997b), and have somewhat similar effects on 
perception and cognition (Vollenweider and Geyer, 2001). Additional support for the convergence of 
serotonergic and glutamatergic systems is derived from the finding that the behavioral effects of 
hallucinogens are potentiated by co-administration of NMDA antagonists (Dall'Olio et al., 1999; 
Winter et al., 2000, 2004; Zhang and Marek, 2008). Recently, evidence has emerged that mGlu2 and 5-
HT2A receptors are co-localized in cortical neurons where they may form functional complexes 
(Gonzalez-Maeso et al., 2008). The existence of a mGlu2/5-HT2A receptor complex is intriguing in 
light of a recent report that a prodrug for a selective mGlu2/3 agonist possesses significant antipsychotic 
efficacy in schizophrenic patients (Patil et al., 2007). 
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Conclusions and future directions 
As reviewed above, considerable evidence derived from converging methods suggests that 
schizophrenia patients display abnormalities in serotonergic function. Nevertheless, different 
approaches intended to measure identical biological markers frequently produced contradictory results 
(e.g, autoradiographic post-mortem studies vs. PET studies). In particular, results from peripheral 
measures (CSF, platelets, blood, hormone response) often did not match findings based upon more 
central parameters of serotonin function (receptor density, brain levels of 5-HT and metabolites).  
Moreover, it was repeatedly shown that some alterations of the 5-HT system reported in schizophrenia 
patients could be explained by chronic treatment with antipsychotic drugs. Despite some 
methodological reservations and the many contradictory results, there is accumulating evidence that 
the 5-HT1A and the 5-HT2A receptor subtypes play an especially important role in schizophrenia. Post-
mortem studies and some PET data suggest that schizophrenia patients display an increase of 5-HT1A 
and a decrease of 5-HT2A receptors especially in the PFC. Genetic variations of the 5-HT2A receptor 
(and perhaps also of the 5-HT1A receptor) appear to contribute to the risk to develop schizophrenia and 
the response to antipsychotic treatment. These genetic variations also appear to be associated with 
endophenotypic markers of schizophrenia, such as sensorimotor gating. Hallucinogenic 5-HT2A 
agonists produce some schizophrenia-like symptoms and also mimic several endophenotypes of 
schizophrenia. In contrast, the hypothesis that a serotonergic action of mechanism is necessary for the 
claimed therapeutic superiority of the so called atypical antipsychotics is not well supported by the 
data so far because a 5-HT antagonistic action seems to be not sufficient for an antipsychotic effect (at 
least on the level of large and heterogenous populations of schizophrenia patients). Nevertheless, 5-
HT1A agonists and 5-HT2C antagonists my have some beneficial effects particularly on cognition and 
negative symptoms. Additionally, agents acting at other 5-HT receptor subtypes (5-HT4, 5-HT6, 5-
HT7) may have some pro-cognitive effects in schizophrenia patients. 
The highly contradictory results regarding serotonergic alterations in schizophrenia might have two 
origins: I.) Alterations of the serotonin system are not sufficient to explain the full picture of 
schizophrenia. This view is supported by the fact that other transmitter systems (e.g., dopamine, 
GABA, glutamate, acetylcholine) and biochemical substrates (e.g. reelin, BDNF, synaptophysin, 
SNAP-25, and complexin II) are also affected in schizophrenia patients. II.) Not all but only a 
subpopulation of the patients within the broad disease cluster schizophrenia display changes in 
serotonin function. This assumption is supported by several studies showing that some patients better 
respond to serotonergic antipsychotic drugs than other patients, that some alterations of the 5-HT 
systems at baseline could predict treatment response, and that serotonergic challenges induce a broad 
range of reactions ranging from improvement to worsening of symptoms, pointing to substantial 
heterogeneity of central serotonergic activity. 
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The 5-HT system is probably only one piece from the enigmatic mosaic of the multifactorial causation 
of the group of schizophrenia spectrum disorders. Specific polymorphisms within the 5-HT system 
might influence e.g. the expression of serotonin receptors during neurogenesis and these changes 
could have an impact on later brain maturation and 5-HT function. But only in combination with 
further neurodevelopmental “hits” (such as pre- and postnatal infections, stressful events or drug use 
during pregnancy, obstetric complications, a stressful adolescence, or further critical life events), and 
other genetic variations (DISC1, VMAT1, GRIN2) could the symptom pattern of a schizophreniform 
disorder arise.  
Future studies should devote more attention to the demarcation of subpopulations of schizophrenia 
patients exhibiting specific changes of the 5-HT system, who could then be successfully treated with 
specific serotonergic drugs. These subpopulations should not only to be characterized by distinct 
biological markers but also by a more precise psychopathological description. Moreover, the 
behavioral consequences of genetic variations within the 5-HT system or of pharmacological 
manipulations of the system might help to better understand disturbed brain functions of schizophrenia 
patients. Finally, recent preclinical data suggest that also alterations in the interaction between the 
serotonin and the glutamate system might have an influence on the development and the symptoms of 
schizophrenia. These interactions should be further investigated in healthy humans and schizophrenia 
patients. 
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